Buried Science

Remedies › Mistletoe extract › Cancer · All remedies for cancer

Mistletoe extract and cancer: what the evidence says

Small or mixed human studies suggest mistletoe injections do not reliably lengthen survival: the best-run placebo-controlled trial found no benefit, while open and observational studies report longer survival.

3/5 Limited

Some human evidence: small trials, trials on a related outcome, or population studies that disagree. How we score

A research summary, not a substitute for treatment. If you or someone you care for has cancer, talk to the oncologist before adding any supplement, and do not delay or replace treatment.

PubMed lists 963 papers on mistletoe and cancer. We read all 29 systematic reviews and meta-analyses, every paper tagged as a trial, and the human studies the search had mislabelled as lab work: 146 abstracts in all. We kept 41 that measured survival or tumour response.

The best-controlled evidence is negative. MISTRAL, a 2024 Swedish trial of 290 people with advanced pancreatic cancer, used placebo injections and found median survival of 7.8 months with mistletoe vs 8.3 with placebo. A randomized melanoma trial of 830 people and a head and neck cancer trial of 477 also found no benefit.

Weaker studies look strongly positive. An open Serbian pancreatic trial without placebo reported 4.8 vs 2.7 months, and registry and record-review studies, mostly from anthroposophic centres or funded by manufacturers, report hazard ratios around 0.4 to 0.6. Pooled analyses find a similar average, but a 2024 analysis showed it vanishes when only randomized trials at low risk of bias are kept (hazard ratio 0.78, 0.30 to 2.00).

Rare complete remissions are reported in single patients given high or local doses. At least six registered trials, including a 174-patient bladder cancer trial, have no published results (see Beyond Google).

The evidence ladder higher rungs count for more
  1. Meta-analyses of trialspooled randomized trials4
  2. Human studiestrials and population studies29
  3. Case reportssingle people3
  4. Animal studiesmostly rodents126
  5. Lab studiescells, test tubes492

The studies in people, read one by one

ResultTypeWhat they didWhat they found
No effectRandomized trial, 2024
290 people		Double-blind, placebo-controlled phase 3 trial (MISTRAL), Sweden; subcutaneous mistletoe extract or placebo three times a week for 9 months on top of standard care, advanced pancreatic cancer
Measured: Overall survival (primary); global quality of life		No survival benefit: adjusted hazard ratio 1.13 (0.89 to 1.44); median survival 7.8 months with mistletoe vs 8.3 with placebo. Skin reactions at the injection site in 66% vs 1%. PubMed 38915151
PositiveRandomized trial, 2013
220 people		Open-label, single-centre randomized phase 3 trial, Serbia; mistletoe extract or no anticancer therapy, both with best supportive care, advanced pancreatic cancer (interim analysis)
Measured: Overall survival		Median survival 4.8 vs 2.7 months, prognosis-adjusted hazard ratio 0.49 (p < 0.0001). No placebo and no blinding; the trial was stopped at this interim analysis. PubMed 23890767
No effectRandomized trial, 2004
830 people		Randomized phase 3 trial (EORTC 18871 / DKG 80-1) after melanoma surgery; the German arm compared Iscador M with observation
Measured: Disease-free interval and overall survival over 8.2 years		No benefit: Iscador M vs observation, disease-free interval hazard ratio 1.32 (0.93 to 1.87), overall survival 1.21 (0.84 to 1.75). PubMed 14746858
No effectRandomized trial, 2001
477 people		Randomized controlled trial, mistletoe lectin-standardised extract after surgery (with or without radiotherapy) for head and neck cancer, Munich
Measured: Disease-free survival, 5-year survival, quality of life		Disease-free survival hazard ratio 0.959 (0.725 to 1.268); 5-year survival no better; no change in immune measures or quality of life. PubMed 11165126
No effectRandomized trial, 2013
72 people		Randomized phase 2 trial, Iscador added to carboplatin chemotherapy vs chemotherapy alone, advanced non-small-cell lung cancer, Israel
Measured: Overall survival, time to progression		Median survival 11 months in both groups; time to progression 6 vs 4.8 months, not significant. (Side-effect results are on the chemotherapy page.) PubMed 23218588
No effectRandomized trial, 2002
45 people		Randomized phase 2 trial, subcutaneous mistletoe lectin after removal of low-grade superficial bladder cancer vs no further treatment
Measured: Recurrence over 18 months		Recurrence-free interval similar (p = 0.76) and number of recurrences comparable (p = 0.48). PubMed 12050495
No effectRandomized trial, 2012
57 people		Five-year follow-up of an open randomized pilot trial, mistletoe extract during CAF chemotherapy vs chemotherapy alone, early breast cancer, Serbia
Measured: Relapse or metastasis within 5 years		Relapse or metastasis in 6 of 28 patients with mistletoe vs 8 of 29 without; no difference. PubMed 23150723
No effectRandomized trial, 2018
95 people		Randomized trial, two mistletoe extracts during adjuvant chemotherapy vs chemotherapy alone, breast cancer, Serbia; financed by the Society for Cancer Research and Helixor
Measured: Safety, relapse or metastasis over 5 years		No difference in relapse or metastasis (p = 0.76); no extra fever. (Quality-of-life results are on the chemotherapy page.) PubMed 30247950
MixedRandomized trial, 2000Randomized trial, mistletoe lectin-standardised extract added to surgery and radiation for malignant glioma, Cologne
Measured: Relapse-free and overall survival		No meaningful difference across all patients; in the stage III/IV subgroup, overall survival 20.05 vs 9.90 months (p = 0.035). PubMed 10928154
PositiveRandomized trial, 2014
20 people		Small open randomized study, subcutaneous Viscum (pine) vs oral etoposide after second relapse of osteosarcoma, Bologna
Measured: Disease-free survival after relapse		Median disease-free survival 39 months with mistletoe vs 4 months with etoposide; compared with an etoposide arm, not with placebo. PubMed 24803944
PositiveRandomized trial, 2003
64 people		Randomized study, Isorel extract plus 5-FU chemotherapy vs chemotherapy alone after surgery for advanced colorectal cancer, Romania
Measured: Survival		Reports significantly better median survival with chemotherapy plus Isorel; the abstract gives no survival figures. PubMed 12667306
PositiveClinical trial, 2006
244 people		Randomized (38 pairs) and non-randomized (84 pairs) matched-pair studies of Iscador in breast cancer, Heidelberg cohort
Measured: Overall survival, time to recurrence		Non-randomized pairs: overall survival hazard ratio 0.43 (0.27 to 0.68); time to recurrence or metastasis mostly favoured Iscador in both designs. PubMed 17057389
MixedSystematic review / meta-analysis, 2010Individual patient data analysis of six matched-pair cohort data sets, breast cancer, Iscador
Measured: Overall survival		Randomized pairs: hazard ratio 0.59 (0.34 to 1.02), not significant; non-randomized pairs: 0.43 (0.34 to 0.56). PubMed 18955332
PositivePopulation study, 2001
10,226 people		Prospective cohort with nested matched-pair studies, several cancers, Germany
Measured: Survival time		In 396 matched pairs, mean survival 4.23 years with Iscador vs 3.05 years without (p < .001). PubMed 11347286
PositivePopulation study, 2004
1,442 people		Retrospective multicentre cohort, Iscador for at least 3 months alongside standard therapy, non-metastatic breast cancer, Germany and Switzerland
Measured: Overall survival; side effects of standard therapy		Adjusted mortality hazard ratio 0.46 (0.22 to 0.96); the mistletoe group had more advanced disease at the start. PubMed 15460213
PositivePopulation study, 2005
686 people		Retrospective multicentre cohort, fermented mistletoe extract after melanoma surgery (stage II-III) vs untreated controls
Measured: Tumour-related survival		Adjusted tumour-related mortality hazard ratio 0.41 (0.23 to 0.71). Compare the randomized EORTC melanoma trial above, which found no benefit. PubMed 15727163
PositivePopulation study, 2009
804 people		Retrospective multicentre cohort, Iscador in stage I-III colorectal cancer, Germany
Measured: Disease-free survival; treatment side effects		Disease-free survival hazard ratio 0.60 (p = .013). PubMed 19883529
PositivePopulation study, 2018
158 people		Registry study (Network Oncology), chemotherapy with or without mistletoe, stage IV non-small-cell lung cancer, Germany
Measured: Overall survival		Median survival 17.0 vs 8.0 months; hazard ratio 0.44 (0.26 to 0.74). Patients chose mistletoe themselves. PubMed 30148853
No effectPopulation study, 2020
275 people		Registry study (Network Oncology), standard therapy with or without mistletoe, stage I-IIIA lung cancer
Measured: Overall survival		No significant survival difference overall; no added effect in patients who had surgery. PubMed 32856476
PositivePopulation study, 2024
415 people		Registry study, PD-1/PD-L1 immunotherapy with or without mistletoe, advanced lung cancer; PubMed lists Abnoba and Helixor as funders
Measured: Overall survival		Median survival 13.8 vs 6.8 months, adjusted hazard ratio 0.60 (0.43 to 0.85). PubMed 38672690
MixedPopulation study, 2025
900 people		Retrospective study after pancreatic cancer surgery, Seoul, AbnobaVISCUM F vs none (propensity-matched); PubMed lists LB ABNOBA as funder
Measured: Disease-free and overall survival		Disease-free survival similar (p = 0.518); overall survival better with mistletoe (p < 0.001). PubMed 41145311
PositivePopulation study, 2026
748 people		Prospective cohort, palliative care for breast cancer, Seoul (time-dependent analysis)
Measured: Overall mortality		Mistletoe therapy associated with lower mortality, hazard ratio 0.463 (0.231 to 0.927); median follow-up 10 months. PubMed 42882789
No effectPopulation study, 2018
18,528 people		Retrospective registry comparison of 164 breast cancer patients given mistletoe lectin with similar untreated patients
Measured: Overall and recurrence-free survival, quality of life		Raw data showed worse survival with mistletoe (p = 0.02), likely from selection; after case matching, no difference in survival or quality of life. PubMed 29491089
PositivePopulation study, 2016
240 people		Registry study, stage IV pancreatic cancer, chemotherapy with or without mistletoe
Measured: Overall survival		Median survival 12.1 months with chemotherapy plus mistletoe vs 7.3 with chemotherapy alone. PubMed 27485618
No effectClinical trial, 1989
14 people		Phase 2 study, Iscador alone, stage IV kidney cancer with lung metastases, Copenhagen
Measured: Tumour response, survival		No tumour responses; median survival 330 days, similar to earlier studies of untreated patients. PubMed 2477047
No effectClinical trial, 2004
25 people		Phase 2 study, Abnoba-viscum alone, metastatic colorectal cancer after 5-FU failed, Israel
Measured: Objective tumour response		No objective responses (0%, 95% CI 0 to 13.7%); stable disease in 21; median survival 5.5 months. PubMed 15456952
PositiveClinical trial, 2004
23 people		Phase 2 study, Viscum fraxini-2 injections alone, advanced liver cancer, Egypt
Measured: Tumour response		3 complete and 2 partial responses; 9 progressed and 9 could not be assessed because of early death. PubMed 14710208
MixedClinical trial, 2023
21 people		Phase 1 dose-finding trial of intravenous Helixor M, Johns Hopkins, heavily pretreated solid tumours
Measured: Safety, tumour response, quality of life		No objective responses; stable disease in 5; disease control rate 23.8%. Grade 3 or worse side effects in 3 patients. PubMed 36860652
No effectClinical trial, 2013
44 people		NCI/NCCAM phase 1 trial, mistletoe extract with gemcitabine, advanced solid tumours
Measured: Safety, response		Partial response 6%, stable disease 42%; authors judged response similar to gemcitabine alone. PubMed 24285980
PositiveClinical trial, 2015
36 people		Single-group dose-escalation study, mistletoe extract instilled into the bladder, non-muscle-invasive bladder cancer
Measured: Marker-tumour remission, 1-year recurrence		Marker tumour remission in 55.6%; recurrence 26.3% at one year. No control group. PubMed 25910967
MixedSystematic review / meta-analysis, 2024
28,298 people		Meta-analysis of 28 controlled studies, overall survival, graded by risk of bias (Jena)
Measured: Overall survival		All studies pooled: hazard ratio 0.61 (0.53 to 0.70). Randomized studies at low risk of bias: 0.78 (0.30 to 2.00), not significant. The positive pooled result depended on low-quality studies. PubMed 38679615
No effectSystematic review / meta-analysis, 2023
663 people		Systematic review and meta-analysis of 7 randomized trials of mistletoe around cancer surgery
Measured: Mortality, recurrence		Mortality risk ratio 1.00 (0.79 to 1.27); recurrence 1.03 (0.79 to 1.33). PubMed 37754510
PositiveSystematic review / meta-analysis, 2022Meta-analysis of 11 randomized trials (plus 8 non-randomized) of non-fermented mistletoe extracts
Measured: Overall survival		Randomized trials pooled: hazard ratio 0.81 (0.69 to 0.95). Not significant once trials with an active comparator were added; moderate risk of bias. PubMed 36324298
PositiveSystematic review / meta-analysis, 2020Meta-analysis of 32 controlled studies of Iscador (55 strata)
Measured: Overall or event-free survival		Pooled hazard ratio 0.59 (0.53 to 0.65); none of the studies was blinded. PubMed 31927541
MixedSystematic review / meta-analysis, 2009Systematic review and meta-analysis of 41 studies of Iscador and survival
Measured: Survival		Pooled hazard ratio 0.59, but the funnel plot showed strong signs of publication bias, and matched-pair studies gave much better results than others. PubMed 20021637
No effectSystematic review / meta-analysis, 2019
2,639 people		Systematic review of 28 publications, survival and safety (Jena)
Measured: Survival, tumour response		Most studies showed no effect on survival, and especially high-quality studies showed no benefit. PubMed 30673873
MixedSystematic review / meta-analysis, 2008
3,484 people		Cochrane review of 21 randomized trials
Measured: Survival, tumour response, quality of life		6 of 13 survival trials showed some benefit, none of high methodological quality; two trials in melanoma and head and neck cancer suggested no effect. Evidence for survival called weak. PubMed 18425885
No effectSystematic review / meta-analysis, 2003Systematic review of 10 randomized trials (Exeter)
Measured: Survival, quality of life		None of the methodologically stronger trials showed efficacy. PubMed 12949804
PositiveCase report, 2017
1 people		Case report, melanoma lymph-node metastases treated only with high-dose, fever-inducing mistletoe (subcutaneous, intravenous, into lesions)
Measured: Tumour response		Complete remission after 2 years; tumour free 3.5 years at publication. A single case cannot show the extract caused it. PubMed 29145317
PositiveCase report, 2022
1 people		Case report, relapsing liver cancer, intravenous mistletoe with L-ornithine-L-aspartate, no other cancer treatment
Measured: Tumour response		Complete regression on imaging, sustained more than 5 years at publication. PubMed 35764068
NegativeCase report, 1998
1 people		Case report, lymphoma patient injecting a mistletoe preparation
Measured: Lymphoma at the injection sites		Lymphoma nodules appeared exactly at the injection sites 5 weeks after starting; no new nodules after injections stopped. PubMed 9739765

Where the sources agree, and where they don’t

3 of 7 kinds of source point toward a benefit, 1 toward no effect or harm, 2 are mixed, and 1 has no data yet. Agreement between independent kinds of evidence matters more than the number of papers in any one of them.

Kind of sourcePoints toDetail
Best-run randomized trialsNo effectMISTRAL, EORTC melanoma, head and neck: no survival benefit
Open or small randomized trialsMixedpancreatic and osteosarcoma positive; bladder, lung, breast null
Meta-analysesMixedpooled HR about 0.6, but not significant in low-bias trials
Observational and registry studiesPositivelarge survival gains, mostly by anthroposophic centres and makers
Case reportsPositiverare remissions with high or local doses; one lymphoma flare
Unpublished registered trialsNo dataat least 6 trials with no results, incl. a 174-patient bladder trial
Public reportsPositive10 of 21 cancer reports say it helped, nearly all alongside other treatment

Beyond Google: 11 findings about Mistletoe extract from trial registries, FDA reports and patent offices that a normal search rarely shows. See them

What people report

We read public first-person posts and counted every outcome, good or bad. 21 reports about this condition, read on 2026-10-28; 5 mention side effects.

  • 10Helped
  • 3No effect
  • 1Got worse
  • 3Mixed
  • 4Too early

Why these counts prove nothing on their own: people who post are not a random sample, most take other treatments at the same time, and nobody checks the diagnosis. We show them because they tell researchers what to test next.

Read all 21 reports
  • Helped Has injected Iscador for more than four years after a late diagnosis and has passed the five-year mark; feels it is helping. Breast Cancer Now forum, 2010-10-02 (Survival alongside standard treatment; poster does not claim proof.)
  • Helped Reports no side effects and remission seven and a half years after a poor-prognosis diagnosis; later adds she cannot know whether Iscador made the difference. Breast Cancer Now forum, 2010-10-03 (Remission after full standard treatment; poster acknowledges uncertainty.)
  • Helped Says her mother took mistletoe for ten years after bowel cancer surgery, declined chemotherapy, and has had no recurrence in twenty years. Breast Cancer Now forum, 2010-10-03 (Second-hand report from a daughter; stage and pathology not given.)
  • Too early Started Iscador privately at a low series because of sensitivities; tolerating it so far and has reached the expected skin reaction. Side effects: injection-site red mark (the intended reaction). Breast Cancer Now forum, 2010-12-03 (No cancer outcome reported.)
  • Helped Took letrozole plus Iscador for five years after a 2006 bone-metastasis diagnosis and reports no cancer since. Breast Cancer Now forum, 2015-11-26 (Letrozole is an effective standard drug and is a strong confounder.)
  • Too early Gave the first mistletoe injection the day before posting and had not yet had the expected skin reaction. Breastcancer.org community, 2025-11 (Just started.)
  • Helped Has just started mistletoe and says it is working well for her condition; main complaint is the practitioner's cost. HealthUnlocked, 2018-09-07 (Very early report; no measure given.)
  • Helped Uses mistletoe injections alongside palbociclib and letrozole and finds them helpful. HealthUnlocked, 2021-08-26 (No measure given; several treatments at once.)
  • Mixed Was cancer free for five and a half years before a recurrence; stopped because of injections, prescription hassle and cost, and has not restarted. Side effects: discomfort of frequent injections. HealthUnlocked, 2021-05-13 (Does not attribute either the remission or the recurrence to mistletoe.)
  • Helped Took Iscador for about three years before radiotherapy and credits it as one of the things that kept the cancer stable; would use it again. HealthUnlocked, 2020-02-03 (Says himself it is impossible to tell which treatment helped.)
  • No effect PSA rose from 17.6 to 31.1 and a scan showed more cancer activity during two months of Iscador, so he stopped it. HealthUnlocked, 2019-04 (No standard treatment; short trial.)
  • Mixed PSA fell to 0.1 with mistletoe among about ten concurrent therapies, mostly credited to hyperthermia and hormone therapy; the colon cancer later spread again. HealthUnlocked, 2019-05 (Mistletoe's part cannot be separated.)
  • Too early After BCG, had three weeks of Iscador by several routes at a Swiss clinic; strong injections brought high fevers. Too early to judge. Side effects: high fever after injections (intended by the clinic). Inspire, 2013-03-21 (Replies are members-only and were not read.)
  • Mixed Says Iscador did not stop her mother's ovarian cancer but did give her pain relief in her last days. Melanoma Research Foundation forum, 2011-08-17 (Second-hand family report.)
  • Helped Reports great results from mistletoe; says her oncologist could not explain the improvement. Inspire, 2019-03-14 (No details of treatment or measures.)
  • Too early After six weeks she cannot tell whether it helps; a strong reaction left a sore, itchy lump and that area became hard to inject. Side effects: sore, itchy lump at the injection site, skin that resisted the needle. Inspire, 2019-05-05 (Early report.)
  • Worse Tried mistletoe a few years earlier and quit because her CA-125 tumour marker rose. Inspire, 2019-05-17 (Marker change only; timing and other treatment not given.)
  • Helped After a year of mistletoe injections and infusions, believes it is a big part of having had no evidence of disease for almost a year. Side effects: scarring at injection sites. Inspire, 2019-06-16 (Many concurrent therapies; prior treatment not described.)
  • No effect Takes one homeopathic mistletoe tablet a day; feels well but cannot say whether it makes any difference. HealthUnlocked, 2021-02 (Homeopathic dilution, not the extract studied in trials.)
  • Helped Her first scan after starting mistletoe showed smaller tumours and healing bone metastases and she feels great, though her tumour marker has climbed again. HealthUnlocked, 2021-02 (Started anastrozole a few months earlier, which can explain the scan; marker rising.)
  • No effect Made his own mistletoe tincture with other herbs over a summer; PSA kept climbing. HealthUnlocked, 2019-04-06 (Home-made oral tincture, not a pharmaceutical extract.)

Every other paper we found

PubMed returned 963 papers for this search on 2026-10-28. We read the human studies above ourselves. The rest are sorted by type automatically from PubMed's labels, which are sometimes wrong. We removed 6 papers that only share a word with this search (such as a trial of a celandine drug called Ukrain, a kidney-transplant surgery study and an elm-bark rat study).

Animal studies 124
  1. Comparative in vitro response of canine, human, and murine osteosarcoma cell lines to resveratrol, homeopathic mistletoe (V.A. CH200), and doxorubicin. Res Vet Sci, 2026
  2. Modulated electro-hyperthermia therapy combined with Korean mistletoe extract treatment exerts a strong anti-tumor activity by enhancing cellular and humoral immune responses in mice. Anim Cells Syst (Seoul), 2025
  3. A randomized placebo-controlled double-blinded study comparing oral and subcutaneous administration of mistletoe extract for the treatment of equine sarcoid disease. J Vet Intern Med, 2024
  4. SIRT1/Nrf2/NF-κB Signaling Mediates Anti-Inflammatory and Anti-Apoptotic Activities of Oleanolic Acid in a Mouse Model of Acute Hepatorenal Damage. Medicina (Kaunas), 2023
  5. Herbal supplements suppress pro-inflammatory cytokines, boost humoral immunity, and modulate adipokines to enhance the productivity traits of rabbit bucks in hot climatic conditions. Trop Anim Health Prod, 2023
  6. Mistletoe (Viscum album L.) extract attenuates ıtraconazole-ınduced acute oxidative stress and hepatocellular ınjury in rats. Pak J Pharm Sci, 2023
  7. Radioprotective effect of mistletoe extract on intestinal toxicity: in vivo study using adult zebrafish. Int J Radiat Biol, 2023
  8. In-Vitro Growth Kinetics of Mesenchymal Stem Cells in Cytotoxicity Tests Using Low-Diluted Viscum Album. Homeopathy, 2023
  9. Hexane fraction of Globimetula braunii induces mitochondria-mediated apoptosis in Plasmodium berghei-infected mice. Toxicol Rep, 2022
  10. Specificity of viscumin revised. As probed with a printed glycan array. Biochimie, 2022
  11. Articulatin B chain induced dendritic cells maturation and driven type I T helper cells and cytotoxic T cells activation. Life Sci, 2022
  12. Mistletoe Extract Targets the STAT3-FOXM1 Pathway to Induce Apoptosis and Inhibits Metastasis in Breast Cancer Cells. Am J Chin Med, 2021
  13. Inhibitory effect of Jangkanghwan (Korean traditional food) on experimental ulcerative colitis in mice. J Food Biochem, 2020
  14. Mistletoe-Based Drugs Work in Synergy with Radio-Chemotherapy in the Treatment of Glioma In Vitro and In Vivo in Glioblastoma Bearing Mice. Evid Based Complement Alternat Med, 2019
  15. Radioprotective effects of mistletoe extract in zebrafish embryos in vivo. Int J Radiat Biol, 2019
  16. Viscothionin purified from mistletoe (Viscum album var. coloratum Ohwi) induces insulin secretion from pancreatic beta cells. J Ethnopharmacol, 2019
  17. Adjuvant Therapy Using Mistletoe Containing Drugs Boosts the T-Cell-Mediated Killing of Glioma Cells and Prolongs the Survival of Glioma Bearing Mice. Evid Based Complement Alternat Med, 2018
  18. Thermosensitive liposomes for triggered release of cytotoxic proteins. Eur J Pharm Biopharm, 2018
  19. Phenolic compounds from Viscum album tinctures enhanced antitumor activity in melanoma murine cancer cells. Saudi Pharm J, 2018
  20. Quantitative analysis of receptor-mediated uptake and pro-apoptotic activity of mistletoe lectin-1 by high content imaging. Sci Rep, 2018
  21. [Kombinierte Anwendung von Strahlentherapie und adjuvanter Therapie mit einem Mistelextrakt (Viscum album L.) zur Behandlung des oralen malignen Melanoms beim Hund: Eine retrospektive Studie]. Complement Med Res, 2017
  22. [Postoperative adjuvante Therapie mit einem Mistelextrakt (Viscum album ssp. album) bei Hündinnen mit Mammatumoren]. Complement Med Res, 2017
  23. Elimination of a Viscumin-Ferromagnetic Nanoparticles Conjugate from the Tumor Nodule in Mice. Bull Exp Biol Med, 2017
  24. Antitumor Effect of KML-B-Treated Dendritic Cells via Induction of Lymphocyte Activation. J Immunol Res, 2017
  25. In Vitro and In Vivo Anti-inflammatory Effects of Struthanthus vulgaris. Planta Med, 2017
  26. Korean mistletoe (Viscum album coloratum) extract regulates gene expression related to muscle atrophy and muscle hypertrophy. BMC Complement Altern Med, 2017
  27. Enhanced anti-oxidative effect of fermented Korean mistletoe is originated from an increase in the contents of caffeic acid and lyoniresinol. Food Funct, 2016
  28. Efficacy of mistletoe for chemical pleurodesis in rats without malignancy. Open Med (Wars), 2015
  29. A study of pharmacokinetic interactions among co-existing ingredients in Viscum coloratum after intravenous administration of three different preparations to rats. Pharmacogn Mag, 2015
  30. A Natural Combination Extract of Viscum album L. Containing Both Triterpene Acids and Lectins Is Highly Effective against AML In Vivo. PLoS One, 2015
  31. Anti-cancer effects of enteric-coated polymers containing mistletoe lectin in murine melanoma cells in vitro and in vivo. Mol Cell Biochem, 2015
  32. Mistletoe alkaloid fractions alleviates carbon tetrachloride-induced liver fibrosis through inhibition of hepatic stellate cell activation via TGF-β/Smad interference. J Ethnopharmacol, 2014
  33. [Viscum album L. (Iscador) in the cat: tolerance, adverse reactions and indications]. Schweiz Arch Tierheilkd, 2014
  34. Korean mistletoe (Viscum album coloratum) extract extends the lifespan of nematodes and fruit flies. Biogerontology, 2014
  35. Comparative study concerning mistletoe viscotoxins antitumor activity. Acta Biol Hung, 2013
  36. Triterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivo. PLoS One, 2013
  37. Extract from mistletoe, Viscum album L., reduces Hsp27 and 14-3-3 protein expression and induces apoptosis in C6 rat glioma cells. Genet Mol Res, 2012
  38. Effects of Viscum album L. extract and quercetin on methotrexate-induced cyto-genotoxicity in mouse bone-marrow cells. Mutat Res, 2012
  39. A novel triterpene extract from mistletoe induces rapid apoptosis in murine B16.F10 melanoma cells. Phytother Res, 2012
  40. Effects of Lens culinaris agglutinin on gene expression of gluconeogenic enzymes in the mouse intestine. J Sci Food Agric, 2012
  41. Viscum album L. extract and quercetin reduce cyclophosphamide-induced cardiotoxicity, urotoxicity and genotoxicity in mice. Asian Pac J Cancer Prev, 2011
  42. TLR4-mediated activation of mouse macrophages by Korean mistletoe lectin-C (KML-C). Biochem Biophys Res Commun, 2010
  43. Effects of Japanese mistletoe lectin on cytokine gene expression in human colonic carcinoma cells and in the mouse intestine. Biomed Res, 2009
  44. Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity. Anticancer Res, 2009
  45. Active Chinese mistletoe lectin-55 enhances colon cancer surveillance through regulating innate and adaptive immune responses. World J Gastroenterol, 2008
  46. Effects of European mistletoe (Viscum album L. subsp. album) extracts on activity rhythms of the Syrian hamsters (Mesocricetus auratus). Nat Prod Res, 2008
  47. Cytotoxic effects of the Viscum album L. extract on Ehrlich tumour cells in vivo. Phytother Res, 2008
  48. Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer Lett, 2008
  49. Modulation of energy metabolic enzyme expression in N-nitrosodiethylamine-mediated hepatocarcinogenesis by Chinese herbs, Huqi San. Biofactors, 2008
  50. Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model. Br J Cancer, 2008
  51. Intratumoral application of standardized mistletoe extracts down regulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model. Anticancer Res, 2006
  52. Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. J Clin Immunol, 2006
  53. Effects of mistletoe extract on murine thymocytes in vivo and on glucocorticoid-induced cell count reduction. Forsch Komplementmed, 2006
  54. Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. Cancer Lett, 2006
  55. [Determination of primary structure of a novel peptide from mistletoe and its antitumor activity]. Yao Xue Xue Bao, 2004
  56. Anti-inflammatory effect of Viscum album agglutinin-I (VAA-I): induction of apoptosis in activated neutrophils and inhibition of lipopolysaccharide-induced neutrophilic inflammation in vivo. Clin Exp Immunol, 2004
  57. A mistletoe lectin (ML-1)-containing diet reduces the viability of a murine non-Hodgkin lymphoma tumor. Cancer Detect Prev, 2004
  58. Cytotoxic effects of some animal and vegetable extracts and some chemicals on liver and colon carcinoma and myosarcoma. Saudi Med J, 2004
  59. Antitumor activity of the Korean mistletoe lectin is attributed to activation of macrophages and NK cells. Arch Pharm Res, 2003
  60. Lectinocytochemical detection of apoptotic murine leukemia L1210 cells. Cytometry A, 2003
  61. Potential role of transforming growth factor beta1 in drug resistance of tumor cells. Acta Biochim Pol, 2003
  62. Indonesian tea mistletoe (Scurrula oortiana) stem extract increases tumour cell sensitivity to tumour necrosis factor alpha (TNFalpha). Phytother Res, 2003
  63. Immunobiological features of the galactoside lectin L-Lc isolated from the Argentine mistletoe Ligaria cuneifolia. J Ethnopharmacol, 2003
  64. Standardized mistletoe extract augments immune response and down-regulates local and metastatic tumor growth in murine models. Anticancer Res, 2002
  65. Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice. Anticancer Res, 2001
  66. Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis. Cancer Biother Radiopharm, 2001
  67. Immunotherapy of C3H/HeJ mammary adenocarcinoma with interleukin-2, mistletoe lectin or their combination. effects on tumour growth, capillary leakage and nitric oxide (NO) production. Eur J Cancer, 2001
  68. Anticancer activity of an aqueous mistletoe extract (AME) in syngeneic murine tumor models. Anticancer Res, 2001
  69. Application of standardized mistletoe extracts augment immune response and down regulates metastatic organ colonization in murine models. Cancer Lett, 2001
  70. An overview on anticancer activities of the Viscum album extract Isorel. Cancer Biother Radiopharm, 2001
  71. Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model. Cancer, 2001
  72. Antiproliferative and anticarcinogenic effects of an aqueous preparation of Abies alba and Viscum album se abies, on a L-1210 malignant cell line and tumor-bearing Wistar rats. Anticancer Res, 2000
  73. Antitumoral effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice. Anticancer Res, 2000
  74. Cell-type dependence of stability modulation of lectin-initiated contacts by impairment of multivalent carbohydrate binding and intracellular signaling. Biosci Rep, 2000
  75. Cytotoxic activity of recombinant bFGF-rViscumin fusion proteins. Biochem Biophys Res Commun, 2000
  76. Role of natural killer cells in iscador mediated inhibition of metastasis by adoptive immunotherapy. Immunol Invest, 2000
  77. Long-term administration of galactoside-specific mistletoe lectin in an animal model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response. J Cancer Res Clin Oncol, 2000
  78. Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice. Cancer Lett, 2000
  79. Mistletoe lectin dissociates into catalytic and binding subunits before translocation across the membrane to the cytoplasm. FEBS Lett, 1999
  80. Inhibition of lung metastasis by adoptive immunotherapy using Iscador. Immunol Invest, 1999
  81. Study of an Argentine mistletoe, the hemiparasite Ligaria cuneifolia (R. et P.) Tiegh. (Loranthaceae). J Ethnopharmacol, 1998
  82. Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration. J Cancer Res Clin Oncol, 1998
  83. Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs. Arzneimittelforschung, 1998
  84. Efficiency of treatment with galactoside-specific lectin from mistletoe against rat glioma. Anticancer Res, 1998
  85. Cytotoxicity of heat-treated Korean mistletoe. Cancer Lett, 1998
  86. Neoglycoproteins with the synthetic complex biantennary nonasaccharide or its alpha 2,3/alpha 2,6-sialylated derivatives: their preparation, assessment of their ligand properties for purified lectins, for tumor cells in vitro, and in tissue sections, and their biodistribution in tumor-bearing mice. Bioconjug Chem, 1997
  87. Lack of an antitumoral effect of immunomodulatory galactoside-specific mistletoe lectin on N-methyl-N-nitrosourea-induced urinary bladder carcinogenesis in rats. Exp Toxicol Pathol, 1997
  88. Effect of viscum album in the inhibition of lung metastasis in mice induced by B16F10 melanoma cells. J Exp Clin Cancer Res, 1997
  89. Immunomodulating efficacy of combined administration of galactoside-specific lectin standardized mistletoe extract and sodium selenite in BALB/c-mice. Anticancer Res, 1997
  90. Viscum album L. preparation Isorel modifies the immune response in normal and in tumour-bearing mice. Anticancer Drugs, 1997
  91. The Viscum album preparation Isorel inhibits the growth of melanoma B16F10 by influencing the tumour-host relationship. Anticancer Drugs, 1997
  92. Anticarcinogenic and antimetastatic activity of Iscador. Anticancer Drugs, 1997
  93. Prevention of 20-methylcholanthrene-induced sarcoma by a mistletoe extract, Iscador. Carcinogenesis, 1996
  94. Inhibitory effect of Korean mistletoe (Viscum album coloratum) extract on tumour angiogenesis and metastasis of haematogenous and non-haematogenous tumour cells in mice. Cancer Lett, 1995
  95. Tumoricidal activity of mouse peritoneal macrophages treated with Viscum album extract. Immunol Invest, 1993
  96. Immunological mechanism of action of the tumor reducing peptide from mistletoe extract (NSC 635089) cellular proliferation. Cancer Lett, 1992
  97. Immunomodulatory activity of a peptide isolated from Viscum album extract (NSC 635 089). Immunol Invest, 1992
  98. Comparative studies on internalization of gold labelled mistletoe lectin I (MLI), its subunits, and of an immunotoxin into mouse L 1210V leukemia cells. Acta Histochem, 1992
  99. The activity of two immunotoxins composed of monoclonal antibody MoAb-16 and A-chain of ricin (MoAb-16-RTA) or A-chain of mistletoe lectin I (MoAb-16-MLIA). Arch Immunol Ther Exp (Warsz), 1992
  100. Cytotoxic norditerpene lactones from Ileostylus micranthus. J Nat Prod, 1991
  101. Internalization and action of an immunotoxin containing mistletoe lectin A-chain. Cancer Res, 1991
  102. Influence of treatment with the immunomodulatory effective dose of the beta-galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems. In Vivo, 1991
  103. Comparative studies on internalization of gold-labelled mistletoe lectin I, its subunits, as well as of an immunotoxin in murine L 1210 leukemia cells. Acta Histochem Suppl, 1991
  104. Effect of a preparation from Viscum album on tumor development in vitro and in mice. J Ethnopharmacol, 1990
  105. Relationship between internalization kinetics and cytotoxicity of mistletoe lectin I to L1210 leukaemia cells. Folia Biol (Praha), 1990
  106. Presence of a receptor for the active component of Iscador in ascites fluid of tumour bearing mice. Cancer Lett, 1989
  107. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res, 1989
  108. Detection and quantification of ligand leakage from lectin affinity columns. Biomed Biochim Acta, 1989
  109. Isolation and identification of a tumour reducing component from mistletoe extract (Iscador). Cancer Lett, 1988
  110. [The effect of Isorel M (Novipharm CMBH) on human breast carcinoma transplanted into athymic (nu/nu) mice]. Cas Lek Cesk, 1986
  111. Biological properties of Pyrularia thionin prepared from nuts of Pyrularia pubera. Toxicon, 1986
  112. Studies on the tumor-inhibiting efficacy of Iscador in experimental animal tumors. J Cancer Res Clin Oncol, 1983
  113. Isolation of biologically active alkaloids from Korean mistletoe Viscum album, coloratum. Experientia, 1980
  114. Cellular and humoral adjuvant activity of mistletoe extract. Immunobiology, 1979
  115. [Isolation and characterization of mistletoe extracts (Viscum album L.). II. Effect of agglutinating and cytotoxic fractions on mouse ascites tumor cells]. Acta Biol Med Ger, 1977
  116. [The agglutination of human erythrocytes and mouse ascites tumor cells by extracts from mistletoe (Viscum album L.)]. Acta Biol Med Ger, 1976
  117. [The effect of Iscador (Viscum praeparatum M.) on the Walker carcinosarcoma of the rat (author's transl)]. Wien Klin Wochenschr, 1975
  118. [The serologic behavior of some commercial Viscum albumin L. preparations, especially Iscador, in relation to human blood cells and mouse ascites tumor cells]. Acta Biol Med Ger, 1974
  119. Thymus stimulation and cancer prophylaxis by Viscum proteins. Experientia, 1970
  120. [Inhibitory influence of basic proteins from Viscum album on RNA synthesis in Yoshida ascites cells]. Hoppe Seylers Z Physiol Chem, 1968
  121. [Data on the substances contained in Viscum album, IV. Biological activity of individual protein fractions]. Hoppe Seylers Z Physiol Chem, 1968
  122. [Cancerostatic protein components from Viscum album]. Experientia, 1965
  123. [Effect of mistletoe preparations on metastatization of the Brown-Pearce rabbit]. Vopr Onkol, 1955
  124. [Effect of preparations of Viscum album on metastatic development of Brown-Pearce rabbit carcinoma]. Vopr Onkol, 1955
Lab studies 491
  1. Systems approach to integrative oncology in breast cancer care: service design, delivery and patient experiences from a UK center. Front Oncol, 2026
  2. Viscum album subsp. austriacum-mediated biosynthesis of magnesium nanoparticles: In vitro anticancer, antibiofilm, and antioxidant activities with computational validation. Biochem Biophys Res Commun, 2026
  3. Exploring biologically-based complementary and alternative medicine use among Irish cancer survivors: findings from a national survey. Oncologist, 2026
  4. Insight into the transfer and accumulation of 210Po and 210Pb in epiphytic plants of Kundapura on the southwest coast of India. Environ Geochem Health, 2026
  5. Medicinal Chemistry of Natural Anti-Skin Cancer Agents: An Evidence-Based Literature Review. Anticancer Agents Med Chem, 2026
  6. Patient-reported outcomes regarding the use of complementary and alternative medicine (CAM) in BCR::ABL1-negative myeloproliferative neoplasias. J Cancer Res Clin Oncol, 2026
  7. Viscum coloratum polysaccharide ameliorates hyperuricemic nephropathy by upregulating Nrf2 to inhibit TGF-β1/Smad3 and NLRP3/ASC/Caspase-1 pathways. J Ethnopharmacol, 2026
  8. Expert-guided approaches to complementary interventions for common side effects of cancer therapies: a practice-based perspective from integrative oncology centers in Baden-Württemberg, Germany. Front Oncol, 2025
  9. Mistletoe Extracts Inhibit Progressive Growth of Prostate Cancer Cells. Cells, 2025
  10. Galactosylated liposomes for targeted encapsulation and enhanced cytotoxicity of Mistletoe Lectin, an antitumoral type 2 ribosome-inactivating protein. Int J Pharm X, 2025
  11. Helixor A enhances natural killer cell activity by induction of PAI-1 expression through the p38/MAPK signaling pathway. Int Immunopharmacol, 2025
  12. Phytochemical Composition and Antioxidant Activity of a Viscum album Mother Tincture. Plants (Basel), 2025
  13. Comparative analysis of IscM and IscQu in feline oral squamous cell carcinoma treatment: cytotoxic and apoptotic insights. Front Vet Sci, 2025
  14. A natural flavagline derivative A2073 inhibits the proliferation of erythroleukemia cells by targeting the MAPK, PI3K, NF-κB, and cell cycle pathways. Bioorg Chem, 2025
  15. A fermented Mistletoe (Viscum album L.) extract elicits markers characteristic for immunogenic cell death driven by endoplasmic reticulum stress in vitro. BMC Complement Med Ther, 2025
  16. Evaluation of the antiproliferative, cytotoxic and phytochemical properties of Zimbabwean medicinal plants used in cancer treatment. BMC Complement Med Ther, 2025
  17. Network pharmacology, bioinformatics analysis, and experimental validation to reveal the target and pharmacological mechanism of DHDK in treating breast cancer. Naunyn Schmiedebergs Arch Pharmacol, 2025
  18. Synergistic Effects of Mistletoe Lectin and Cisplatin on Triple-Negative Breast Cancer Cells: Insights from 2D and 3D In Vitro Models. Int J Mol Sci, 2025
  19. Complementary Treatment of Breast Cancer Cells with Different Metastatic Potential with Iscador Qu in the Presence of Clinically Approved Anticancer Drugs. Curr Issues Mol Biol, 2024
  20. IGFBP6 Modulates Proteostasis by Activating ATF4 Targets and Reducing ER Retrotranslocon Expression. Dokl Biochem Biophys, 2024
  21. Correction: Immunomodulatory activity and inhibitory effects of Viscum album on cancer cells, its safety profiles and recent nanotechnology development. Planta Med, 2024
  22. Modulation of Breast Cancer Cell Apoptosis and Macrophage Polarization by Mistletoe Lectin in 2D and 3D Models. Int J Mol Sci, 2024
  23. Mistletoe and Pancreatic Cancer. Dtsch Arztebl Int, 2024
  24. Chronobiology of Viscum album L.: a time series of daily metabolomic fingerprints spanning 27 years. Front Physiol, 2024
  25. Pharmakokinetics of Mistletoe Lectins after Intravenous Application of a Mistletoe Product in Healthy Subjects. Pharmaceuticals (Basel), 2024
  26. Anti-melanoma and antioxidant properties of the methanol extract from the leaves of Phragmenthera capitata (Spreng.) Balle and Globimetula braunii (Engl.) Van Tiegh. J Complement Integr Med, 2024
  27. Viscum album, as alternative and bridge to palliative chemotherapy in recurrent gallbladder cancer following laparoscopic radical cholecystectomy: a case report. Korean J Clin Oncol, 2023
  28. Patients with Advanced Pancreatic Cancer Treated with Mistletoe and Hyperthermia in Addition to Palliative Chemotherapy: A Retrospective Single-Center Analysis. Cancers (Basel), 2023
  29. Mistletoe Extracts from Different Host Trees Disparately Inhibit Bladder Cancer Cell Growth and Proliferation. Cancers (Basel), 2023
  30. The Introspective Patient Experience of Mistletoe Therapy in Cancer: A Qualitative Study. Integr Cancer Ther, 2023
  31. Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells for the treatment of monocytic leukemia. Bioengineered, 2023
  32. Which is the More Effective Option for Pleurodesis to Prevent the Recurrence of Malignant Pleural Effusion? Large-Particle Talc or Mistletoe Extract (ABNOVA Viscum Injection). J Chest Surg, 2023
  33. Viscum album Induces Apoptosis by Regulating STAT3 Signaling Pathway in Breast Cancer Cells. Int J Mol Sci, 2023
  34. Inhibition of osteosarcoma by European Mistletoe derived val-miR218. Extracell Vesicles Circ Nucl Acids, 2023
  35. Diagnosis and Treatment of Patients Utilizing Complementary Medicine at a Tertiary Referral Hospital in Eastern Switzerland. Complement Med Res, 2023
  36. Expression, purification, characterization, and cytotoxic evaluation of the ML1-STxB fusion protein. Arch Microbiol, 2023
  37. Antitumor Effect of Iscador on Breast Cancer Cell Lines with Different Metastatic Potential. Int J Mol Sci, 2023
  38. Investigations on the morpho-anatomy and histochemistry of the European mistletoe: Viscum album L. subsp. album. Sci Rep, 2023
  39. Computational evaluation of bioactive compounds from Viscum album (mistletoe) as inhibitors of p63 for pancreatic cancer treatment. J Biomol Struct Dyn, 2023
  40. Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe. Altern Ther Health Med, 2023
  41. Characterization of Viscum album L. Effect on Immune Escape Proteins PD-L1, PD-L2, and MHC-I in the Prostate, Colon, Lung, and Breast Cancer Cells. Complement Med Res, 2023
  42. Seroma prevention with topical Abnobaviscum sclerotherapy following excision of giant cervical lipoma. Arch Craniofac Surg, 2023
  43. Lay etiology concepts of cancer patients do not correlate with their usage of complementary and/or alternative medicine. J Cancer Res Clin Oncol, 2023
  44. Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer. Cancer Med, 2023
  45. Toxicity test of flavonoid compounds from the leaves of Dendrophthoe pentandra (L.) Miq. using in vitro culture cell models. Vet World, 2022
  46. Pluronic® F127 Thermoresponsive Viscum album Hydrogel: Physicochemical Features and Cellular In Vitro Evaluation. Pharmaceutics, 2022
  47. Phytochemical Profile and Antioxidant Capacity of Viscum album L. Subsp. album and Effects on Its Host Trees. Plants (Basel), 2022
  48. Viscum album mother tinctures: Harvest conditions and host trees influence the plant metabolome and the glycolytic pathway of breast cancer cells. Front Pharmacol, 2022
  49. Selective Immune Modulating Activities of Viscum album and Its Components; A Possibility of Therapeutics on Skin Rash Induced by EGFR Inhibitors. Integr Cancer Ther, 2022
  50. Phytochemical Screening, Antioxidant and Antibacterial Properties of Extracts of Viscum continuum E. Mey. Ex Sprague, a South African Mistletoe. Plants (Basel), 2022
  51. Herb-anticancer drug interactions in real life based on VigiBase, the WHO global database. Sci Rep, 2022
  52. Correction: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One, 2022
  53. Comparative Assessment of the Antioxidant and Anticancer Activities of Plicosepalus acacia and Plicosepalus curviflorus: Metabolomic Profiling and In Silico Studies. Antioxidants (Basel), 2022
  54. General practitioners' communication on complementary and integrative medicine for cancer patients: Findings from an analysis of consultations with standardised patients. Eur J Cancer Care (Engl), 2022
  55. LC/MS analysis of Viscum cruciatum Sieber ex Boiss. extract with anti-proliferative activity against MCF-7 cell line via G0/G1 cell cycle arrest: An in-silico and in-vitro study. J Ethnopharmacol, 2022
  56. A pilot study of the mistletoe and breast cancer (MAB) trial: a protocol for a randomised double-blind controlled trial. Pilot Feasibility Stud, 2022
  57. European Mistletoe (Viscum album) Extract Is Cytotoxic to Canine High-Grade Astrocytoma Cells In Vitro and Has Additive Effects with Mebendazole. Vet Sci, 2022
  58. Chemical constituents of Viscum coloratum (Kom.) Nakai and their cytotoxic activities. Nat Prod Res, 2022
  59. Spatial structure and oligomerization of viscotoxin A3 in detergent micelles: Implication for mechanisms of ion channel formation and membrane lysis. Biochem Biophys Res Commun, 2021
  60. [Lectins in Viscum:a progress review]. Zhongguo Zhong Yao Za Zhi, 2021
  61. Inventorization of traditional ethnobotanical uses of wild plants of Dawarian and Ratti Gali areas of District Neelum, Azad Jammu and Kashmir Pakistan. PLoS One, 2021
  62. Untargeted metabolomics approach to discriminate mistletoe commercial products. Sci Rep, 2021
  63. Distinct Modulatory Effects of Fever-Range Hyperthermia on the Response of Breast Cancer Cells and Macrophages to Mistletoe (Viscum album L.) Extract. Pharmaceuticals (Basel), 2021
  64. [Complementary medicine in uro-oncology]. Urologe A, 2021
  65. Complementary and Alternative Medicine for the Treatment of Gliomas: Scoping Review of Clinical Studies, Patient Outcomes, and Toxicity Profiles. World Neurosurg, 2021
  66. [Integrative Oncology for Women with Breast Cancer]. Ther Umsch, 2021
  67. [Präklinische Untersuchungen von Wechselwirkungen zwischen Mistel und Radio- oder Chemotherapie auf pädiatrische Tumorzellen]. Complement Med Res, 2021
  68. Gynecologists' attitudes toward and use of complementary and integrative medicine approaches: results of a national survey in Germany. Arch Gynecol Obstet, 2021
  69. Anticancer Effects of Viscum album Fraxini Extract on Medulloblastoma Cells in vitro. Complement Med Res, 2021
  70. Intracellular Transport of Ribosome-Inactivating Proteins Depends on Annexin 13. Dokl Biochem Biophys, 2020
  71. Comparison of gamma irradiation and heating treatment on cytotoxicity, insulinotropic activity, and molecular structure change of mistletoe viscothionin. Food Sci Biotechnol, 2020
  72. Relationship between the Expression Level of PSMD11 and Other Proteasome Proteins with the Activity of Ricin and Viscumin. Dokl Biochem Biophys, 2020
  73. Comprehensive Metabolome Analysis of Fermented Aqueous Extracts of Viscum album L. by Liquid Chromatography-High Resolution Tandem Mass Spectrometry. Molecules, 2020
  74. Viscum album L. homogenizer-assisted and ultrasound-assisted extracts as potential sources of bioactive compounds. J Food Biochem, 2020
  75. Novel drug isolated from mistletoe (1E,4E)-1,7-bis(4-hydroxyphenyl)hepta-1,4-dien-3-one for potential treatment of various cancers: synthesis, pharmacokinetics and pharmacodynamics. RSC Adv, 2020
  76. Phytochemical analysis and in vitro anti-proliferative activity of Viscum album ethanolic extracts. BMC Complement Med Ther, 2020
  77. Mistletoe-Extract Drugs Stimulate Anti-Cancer Vγ9Vδ2 T Cells. Cells, 2020
  78. Transiently Expressed Mistletoe Lectin II in Nicotiana benthamiana Demonstrates Anticancer Activity In Vitro. Molecules, 2020
  79. Construction of eco-biosensor and its potential application for highly selective, sensitive and fast detection of viscumin. Anal Chim Acta, 2020
  80. Statement to an Insufficient Systematic Review on Viscum album L. Therapy. Evid Based Complement Alternat Med, 2020
  81. Ultrasound-Sensitive Liposomes for Triggered Macromolecular Drug Delivery: Formulation and In Vitro Characterization. Front Pharmacol, 2019
  82. Preclinical Evaluation of Antitumoral and Cytotoxic Properties of Viscum album Fraxini Extract on Pediatric Tumor Cells. Planta Med, 2019
  83. Expanding the chemical diversity of an endophytic fungus Bulgaria inquinans, an ascomycete associated with mistletoe, through an OSMAC approach. RSC Adv, 2019
  84. How far we have gone in realizing true potential of Viscum album as versatile regulator of cell signaling pathways. Cell Mol Biol (Noisy-le-grand), 2019
  85. Herb-drug interactions: a novel algorithm-assisted information system for pharmacokinetic drug interactions with herbal supplements in cancer treatment. Eur J Clin Pharmacol, 2019
  86. Comparison of microbial and transient expression (tobacco plants and plant-cell packs) for the production and purification of the anticancer mistletoe lectin viscumin. Biotechnol Bioeng, 2019
  87. Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression. Sci Rep, 2019
  88. ERRATUM TO: Long-Term Tumor-Free Survival in a Patient with Stage IV Epithelial Ovarian Cancer Undergoing High-Dose Chemotherapy and Viscum album Extract Treatment: A Case Report. Perm J, 2019
  89. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro. BMC Complement Altern Med, 2019
  90. Anticolitic Effect of Viscum coloratum through Suppression of Mast Cell Activation. Am J Chin Med, 2019
  91. 1,7-Bis(4-hydroxyphenyl)-1,4-heptadien-3-one induces lung cancer cell apoptosis via the PI3K/Akt and ERK1/2 pathways. J Cell Physiol, 2019
  92. Intralesional and subcutaneous application of Viscum album L. (European mistletoe) extract in cervical carcinoma in situ: A CARE compliant case report: Erratum. Medicine (Baltimore), 2018
  93. The Internal Coherence of Breast Cancer Patients Is Associated with the Decision-Making for Chemotherapy and Viscum album L. Treatment. Evid Based Complement Alternat Med, 2018
  94. Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy. BMC Complement Altern Med, 2018
  95. Taraxacum officinale extract shows antitumor effects on pediatric cancer cells and enhance mistletoe therapy. Complement Ther Med, 2018
  96. Integrative cancer care in a certified Cancer Centre of a German Anthroposophic hospital. Complement Ther Med, 2018
  97. Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients. Medicines (Basel), 2018
  98. The Subjective Dimension of Integrative Cancer Care: A Qualitative Study Exploring the Perspectives, Themes, and Observations of Experienced Doctors from the Area of Anthroposophic Medicine. Explore (NY), 2018
  99. [Ribosome Inactivation and the Integrity of the Intestinal Epithelial Barrier]. Mol Biol (Mosk), 2018
  100. Crystal Structure of Mistletoe Lectin I (ML-I) from Viscum album in Complex with 4-N-Furfurylcytosine at 2.85 Å Resolution. Med Chem, 2018
  101. The Stability of Medicinal Plant microRNAs in the Herb Preparation Process. Molecules, 2018
  102. GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway. Sci Rep, 2018
  103. Korean mistletoe lectin enhances natural killer cell cytotoxicity via upregulation of perforin expression. Asian Pac J Allergy Immunol, 2018
  104. Viscum articulatum Burm. f. aqueous extract exerts antiproliferative effect and induces cell cycle arrest and apoptosis in leukemia cells. J Ethnopharmacol, 2018
  105. Implementation of an Integrative Oncological Concept in the Daily Care of a German Certified Breast Cancer Center. Complement Med Res, 2018
  106. Malignant Pleural Effusions: Mistletoe Spray Instead of Talc Poudrage? Respiration, 2018
  107. Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities. BMC Complement Altern Med, 2017
  108. Mistletoe (Viscum album) extract targets Axl to suppress cell proliferation and overcome cisplatin- and erlotinib-resistance in non-small cell lung cancer cells. Phytomedicine, 2017
  109. Identification of Viscum album L. miRNAs and prediction of their medicinal values. PLoS One, 2017
  110. Correction: Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model. PLoS One, 2017
  111. Synergistic Antitumour Properties of viscumTT in Alveolar Rhabdomyosarcoma. J Immunol Res, 2017
  112. Simultaneous identification and quantification of the common compounds of Viscum coloratum and its corresponding host plants by ultra-high performance liquid chromatography with quadrupole time-of-flight tandem mass spectrometry and triple quadrupole mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2017
  113. Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model. PLoS One, 2017
  114. iTRAQ-Based Quantitative Proteomic Analysis of the Inhibitory Effects of Polysaccharides from Viscum coloratum (Kom.) Nakai on HepG2 Cells. Sci Rep, 2017
  115. Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells. Sci Rep, 2017
  116. Viscum album (L.) in experimental animal tumors: A meta-analysis. Exp Ther Med, 2017
  117. Proteomic fingerprinting of mistletoe (Viscum album L.) via combinatorial peptide ligand libraries and mass spectrometry analysis. J Proteomics, 2017
  118. Transcriptomic and proteomic insight into the effects of a defined European mistletoe extract in Ewing sarcoma cells reveals cellular stress responses. BMC Complement Altern Med, 2017
  119. Safety of herbal medicine use during chemotherapy in patients with ovarian cancer: a "bedside-to-bench" approach. Med Oncol, 2017
  120. Mistletoe and Garlic Extracts as Polyurethane Carriers - A Possible Remedy for Choroidal Melanoma. Curr Drug Deliv, 2017
  121. Viscumins functionally modulate cell motility-associated gene expression. Int J Oncol, 2017
  122. ViscumTT induces apoptosis and alters IAP expression in osteosarcoma in vitro and has synergistic action when combined with different chemotherapeutic drugs. BMC Complement Altern Med, 2017
  123. Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays. Nutr Cancer, 2017
  124. Articulatin-D induces apoptosis via activation of caspase-8 in acute T-cell leukemia cell line. Mol Cell Biochem, 2017
  125. Anti-Proliferative Effects of Dendrophthoe pentandra Methanol Extract on BCR/ABL-Positive and Imatinib-Resistant Leukemia Cell Lines. Asian Pac J Cancer Prev, 2016
  126. Pro-apoptotic and cytotoxic effects of enriched fraction of Elytranthe parasitica (L.) Danser against HepG2 Hepatocellular carcinoma. BMC Complement Altern Med, 2016
  127. Dendrophthoe pentandra (L.) Miq extract effectively inhibits inflammation, proliferation and induces p53 expression on colitis-associated colon cancer. BMC Complement Altern Med, 2016
  128. Multiple Active Compounds from Viscum album L. Synergistically Converge to Promote Apoptosis in Ewing Sarcoma. PLoS One, 2016
  129. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro. BMC Complement Altern Med, 2016
  130. Antioxidant, Antinociceptive and CNS Activities of Viscum orientale and High Sensitive Quantification of Bioactive Polyphenols by UPLC. Front Pharmacol, 2016
  131. Differential Effects of Viscum album Preparations on the Maturation and Activation of Human Dendritic Cells and CD4⁺ T Cell Responses. Molecules, 2016
  132. Antioxidant Activity and ROS-Dependent Apoptotic Effect of Scurrula ferruginea (Jack) Danser Methanol Extract in Human Breast Cancer Cell MDA-MB-231. PLoS One, 2016
  133. Purification, characterization and anti-proliferation activities of polysaccharides extracted from Viscum coloratum (Kom.) Nakai. Carbohydr Polym, 2016
  134. Intravenous Mistletoe Treatment in Integrative Cancer Care: A Qualitative Study Exploring the Procedures, Concepts, and Observations of Expert Doctors. Evid Based Complement Alternat Med, 2016
  135. Preparation of Viscumin-Ferromagnetic Particles Conjugate and Study of Its Internalization by Human Glioblastoma A172 Cells. Bull Exp Biol Med, 2016
  136. Individualized Integrative Cancer Care in Anthroposophic Medicine: A Qualitative Study of the Concepts and Procedures of Expert Doctors. Integr Cancer Ther, 2016
  137. Proliferation, Apoptosis and Invasion effects of mistletoe alkali on human osteosarcoma U2OS in vitro. Int Surg, 2016
  138. Cytotoxicity and Antiproliferative Activity Assay of Clove Mistletoe (Dendrophthoe pentandra (L.) Miq.) Leaves Extracts. Adv Pharmacol Sci, 2016
  139. Impact of Mistletoe Triterpene Acids on the Uptake of Mistletoe Lectin by Cultured Tumor Cells. PLoS One, 2016
  140. Sensitization of K562 Leukemia Cells to Doxorubicin by the Viscum album Extract. Phytother Res, 2016
  141. Adjuvant Cancer Biotherapy by Viscum Album Extract Isorel: Overview of Evidence Based Medicine Findings. Coll Antropol, 2015
  142. Viscum Album Var Hot Water Extract Mediates Anti-cancer Effects through G1 Phase Cell Cycle Arrest in SK-Hep1 Human Hepatocarcinoma cells. Asian Pac J Cancer Prev, 2015
  143. Cytotoxic activity of Macrosolen parasiticus (L.) Danser on the growth of breast cancer cell line (MCF-7). Pharmacogn Mag, 2015
  144. Tumour cell derived effects on monocyte/macrophage polarization and function and modulatory potential of Viscum album lipophilic extract in vitro. BMC Complement Altern Med, 2015
  145. Viscum album (mistletoe) for pancreatic cancer, electromagnetic field therapy for osteoarthritis, homeopathy for multidrug-resistant tuberculosis, vitamin D for depression, acupuncture for insomnia. Explore (NY), 2015
  146. Viscum album-mediated COX-2 inhibition implicates destabilization of COX-2 mRNA. PLoS One, 2015
  147. Mistletoe treatment as homeopathic magic. Dtsch Arztebl Int, 2015
  148. Wishes and beliefs of cancer patients regarding counseling on integrative medicine. Breast Care (Basel), 2014
  149. Acute pneumonitis consequent on pleurodesis with Viscum album extract: severe chest images but benign clinical course. Multidiscip Respir Med, 2014
  150. [Importance of complementary medicine approaches for patients with prostate cancer]. Urologe A, 2014
  151. Mistletoe treatment for cancer--promising or passé? Dtsch Arztebl Int, 2014
  152. Effects of aqueous soybean, mistletoe and red clover extracts on activities of adenosine deaminase and xanthine oxidase enzyme. Bratisl Lek Listy, 2014
  153. Mistletoe: from basic research to clinical outcomes in cancer and other indications. Evid Based Complement Alternat Med, 2014
  154. Protein Fractions from Korean Mistletoe (Viscum Album coloratum) Extract Induce Insulin Secretion from Pancreatic Beta Cells. Evid Based Complement Alternat Med, 2014
  155. Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study. Evid Based Complement Alternat Med, 2014
  156. Synergistic anticancer effects of lectin and doxorubicin in breast cancer cells. Mol Cell Biochem, 2014
  157. Evaluation of Preclinical Assays to Investigate an Anthroposophic Pharmaceutical Process Applied to Mistletoe (Viscum album L.) Extracts. Evid Based Complement Alternat Med, 2014
  158. Enhanced dendritic cell maturation by the B-chain of Korean mistletoe lectin (KML-B), a novel TLR4 agonist. Int Immunopharmacol, 2014
  159. Online survey of patients with breast cancer on complementary and alternative medicine. Breast Care (Basel), 2014
  160. Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patients. Inflamm Allergy Drug Targets, 2014
  161. Dendrophthoe falcata (L.f) Ettingsh (Neem mistletoe): a potent bioresource to fabricate silver nanoparticles for anticancer effect against human breast cancer cells (MCF-7). Spectrochim Acta A Mol Biomol Spectrosc, 2014
  162. Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients. Evid Based Complement Alternat Med, 2014
  163. [Mistletoe therapy is not consistent with good clinical practice]. Lakartidningen, 2014
  164. Survey of German non-medical practitioners regarding complementary and alternative medicine in oncology. Oncol Res Treat, 2014
  165. Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complement Altern Med, 2014
  166. Emerging roles of mistletoes in malignancy management. 3 Biotech, 2014
  167. Mistletoe: for cancer or just for Christmas? Lancet Oncol, 2013
  168. Network Oncology (NO)--a clinical cancer register for health services research and the evaluation of integrative therapeutic interventions in anthroposophic medicine. Forsch Komplementmed, 2013
  169. An ethnobotanical study of medicinal plants used by the local people of Alaşehir (Manisa) in Turkey. J Ethnopharmacol, 2013
  170. Cytotoxic effects of mistletoe (Viscum album L.) in head and neck squamous cell carcinoma cell lines. Oncol Rep, 2013
  171. Barriers and challenges in integration of anthroposophic medicine in supportive breast cancer care. Springerplus, 2013
  172. Effect of gamma irradiation on mistletoe (Viscum album) lectin-mediated toxicity and immunomodulatory activity. FEBS Open Bio, 2013
  173. Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy. Cancer Immunol Immunother, 2013
  174. Novel GHB-derived natural products from European mistletoe (Viscum album). Pharm Biol, 2013
  175. Korean mistletoe lectin promotes proliferation and invasion of trophoblast cells through regulation of Akt signaling. Reprod Toxicol, 2013
  176. [If the patient has mistletoe wishes]. Rev Med Suisse, 2013
  177. Flavonoids bearing an O-arabinofuranosyl-(1-->3)-rhamnoside moiety from Cladocolea micrantha: inhibitory effect on human melanoma cells. Nat Prod Commun, 2012
  178. Fermented mistletoe extract as a multimodal antitumoral agent in gliomas. Evid Based Complement Alternat Med, 2012
  179. Recombinant VAA-I from Viscum album induces apoptotic cell death of hepatocellular carcinoma SMMC7721 cells. Molecules, 2012
  180. Apoptosis of K562 leukemia cells by Abnobaviscum F®, a European mistletoe extract. Oncol Rep, 2012
  181. Korean mistletoe lectin regulates self-renewal of placenta-derived mesenchymal stem cells via autophagic mechanisms. Cell Prolif, 2012
  182. Apoptosis-induced cell death due to oleanolic acid in HaCaT keratinocyte cells--a proof-of-principle approach for chemopreventive drug development. Asian Pac J Cancer Prev, 2012
  183. Cytotoxic constituents of Viscum coloratum. Z Naturforsch C J Biosci, 2012
  184. A new development of triterpene acid-containing extracts from Viscum album L. displays synergistic induction of apoptosis in acute lymphoblastic leukaemia. Cell Prolif, 2012
  185. Nodal anaplastic large-cell lymphoma ALK-1- with CD30+ cutaneous lymphoproliferation treated with mistletoe: spontaneous remission or treatment response? Klin Padiatr, 2011
  186. Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2. PLoS One, 2011
  187. Case reports of sarcoma patients with optimized lectin-oriented mistletoe extract therapy. J Altern Complement Med, 2011
  188. Mistletoe in tumour therapy. Basic research and clinical practice. Abstracts of the Mistletoe Symposium. November 10-12, 2011. Nonnweiler, Germany. Phytomedicine, 2011
  189. A cytotoxic type-2 ribosome inactivating protein (from leafless mistletoe) lacking sugar binding activity. Int J Biol Macromol, 2011
  190. Viscolin reduces VCAM-1 expression in TNF-α-treated endothelial cells via the JNK/NF-κB and ROS pathway. Free Radic Biol Med, 2011
  191. Symmetric dithiodigalactoside: strategic combination of binding studies and detection of selectivity between a plant toxin and human lectins. Org Biomol Chem, 2011
  192. [Mistletoe in cancer treatment]. Dtsch Med Wochenschr, 2011
  193. Targeting the oncogenic role of miRNA in human cancer using naturally occurring compounds. Br J Pharmacol, 2011
  194. Differences in CD75s- and iso-CD75s-ganglioside content and altered mRNA expression of sialyltransferases ST6GAL1 and ST3GAL6 in human hepatocellular carcinomas and nontumoral liver tissues. Glycobiology, 2011
  195. Down-regulation of some miRNAs by degrading their precursors contributes to anti-cancer effect of mistletoe lectin-I. Br J Pharmacol, 2011
  196. Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine. Evid Based Complement Alternat Med, 2011
  197. Mistletoe lectin transport by M-cells in follicle-associated epithelium (FAE) and IL-12 secretion in dendritic cells situated below FAE in vitro. Arch Pharm Res, 2010
  198. Mistletoe lectin-I augments antiproliferative effects of the PPARgamma agonist rosiglitazone on human malignant melanoma cells. Phytother Res, 2010
  199. In vitro investigation into the potential of a mistletoe extract to alleviate adverse effects of cyclophosphamide. Altern Ther Health Med, 2010
  200. Investigation of the proliferation, apoptosis/necrosis, and cell cycle phases in several human multiple myeloma cell lines. Comparison of Viscum album QuFrF extract with vincristine in an in vitro model. ScientificWorldJournal, 2010
  201. Cytotoxic effect of mistletoe (Viscum album L.) extract on Jurkat cells and its interaction with doxorubicin. Phytother Res, 2010
  202. Mistletoe lectin binds to multidrug resistance-associated protein MRP5. Anticancer Res, 2009
  203. [Mistletoe therapy in cancer treatment: pros and cons]. MMW Fortschr Med, 2009
  204. Linguistic processing and classification of semi structured bibliographic data on complementary medicine. Cancer Inform, 2009
  205. Mistletoe lectin modulates intestinal epithelial cell-derived cytokines and B cell IgA secretion. Arch Pharm Res, 2009
  206. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res, 2009
  207. Mistletoe treatment in cancer-related fatigue: a case report. Cases J, 2009
  208. Screening of fusion partners for high yield expression and purification of bioactive viscotoxins. Protein Expr Purif, 2009
  209. Mistletoe Preparation Iscador: Are there Methodological Concerns with Respect to Controlled Clinical Trials? Evid Based Complement Alternat Med, 2009
  210. Cytotoxic activities of extracts and compounds from Viscum coloratum and its transformation products by Rhodobacter sphaeroides. Appl Biochem Biotechnol, 2009
  211. Small angle neutron scattering as sensitive tool to detect ligand-dependent shape changes in a plant lectin with beta-trefoil folding and their dependence on the nature of the solvent. Glycoconj J, 2009
  212. Comparison of Viscum album QuFrF extract with vincristine in an in vitro model of human B cell lymphoma WSU-1. Arzneimittelforschung, 2008
  213. Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer. Mol Cancer Ther, 2008
  214. Local reactions to treatments with Viscum album L. extracts and their association with T-lymphocyte subsets and quality of life. Anticancer Res, 2008
  215. Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients. Xenobiotica, 2008
  216. Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer, 2008
  217. Calix[n]arene-based glycoclusters: bioactivity of thiourea-linked galactose/lactose moieties as inhibitors of binding of medically relevant lectins to a glycoprotein and cell-surface glycoconjugates and selectivity among human adhesion/growth-regulatory galectins. Chembiochem, 2008
  218. In silico modulation of apoptotic Bcl-2 proteins by mistletoe lectin-1: functional consequences of protein modifications. J Cell Biochem, 2008
  219. Mistletoe in tumour therapy. Abstracts of the 4th Mistletoe Symposium, 8-10 November 2007, Nonnweiler-Otzenhausen, Germany. Phytomedicine, 2007
  220. Isolation and characterization of two Korean mistletoe lectins. J Biochem Mol Biol, 2007
  221. Effects of Korean mistletoe lectin (Viscum album coloratum) on proliferation and cytokine expression in human peripheral blood mononuclear cells and T-lymphocytes. Arch Pharm Res, 2007
  222. In vitro immunoregulatory effects of Korean mistletoe lectin on functional activation of monocytic and macrophage-like cells. Biol Pharm Bull, 2007
  223. Abstracts of the 4th Mistletoe Symposium, Mistletoe in Tumour Therapy. Basic Research and Medicinal Use, 8-10 November 2007. Phytomedicine, 2007
  224. Viscum album agglutinin-I induces degradation of cytoskeletal proteins in leukaemia PLB-985 cells differentiated toward neutrophils: cleavage of non-muscle myosin heavy chain-IIA by caspases. Br J Haematol, 2007
  225. Mechanisms involved in Korean mistletoe lectin-induced apoptosis of cancer cells. World J Gastroenterol, 2007
  226. A lectin from Chinese mistletoe increases gammadelta T cell-mediated cytotoxicity through induction of caspase-dependent apoptosis. Acta Biochim Biophys Sin (Shanghai), 2007
  227. [Complementary and alternative medicines taken by cancer patients]. Bull Cancer, 2007
  228. Suppressive effect of a standardized mistletoe extract on the expression of activatory NK receptors and function of human NK cells. J Clin Immunol, 2007
  229. Mistletoe lectin is not the only cytotoxic component in fermented preparations of Viscum album from white fir (Abies pectinata). BMC Complement Altern Med, 2007
  230. Prolonged cytotoxic effect of aqueous extracts from dried viscum album on bladder cancer cells. Pharmazie, 2007
  231. Solubility studies of oleanolic acid and betulinic acid in aqueous solutions and plant extracts of Viscum album L. Planta Med, 2007
  232. Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro. Anticancer Res, 2007
  233. The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells. Anticancer Res, 2007
  234. Association of complementary methods with quality of life and life satisfaction in patients with gynecologic and breast malignancies. Support Care Cancer, 2007
  235. Improvement of an enzyme linked lectin assay to determine recombinant mistletoe lectin I. J Pharm Biomed Anal, 2007
  236. Methodological artifacts in the assessment for (anti-) proliferative activities of mistletoe extracts. Pediatr Blood Cancer, 2007
  237. Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. Curr Oncol, 2006
  238. Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1. Curr Oncol, 2006
  239. Mistletoe as a treatment for cancer. BMJ, 2006
  240. Paediatric medulloblastoma cells are susceptible to Viscum album (Mistletoe) preparations. Anticancer Res, 2006
  241. The mistletoe and cyst-fluid analysis: a sticky insight. Gastrointest Endosc, 2006
  242. Molecular characterization of the recombinant A-chain of a type II ribosome-inactivating protein (RIP) from Viscum album coloratum and structural basis on its ribosome-inactivating activity and the sugar-binding properties of the B-chain. J Biochem Mol Biol, 2006
  243. Gene expression profiles of different breast cancer cells compared with their responsiveness to fermented mistletoe (Viscum album L.) extracts Iscador from oak (Quercus), pine (Pinus), white fir (Abies) and apple tree (Malus) in vitro. Arzneimittelforschung, 2006
  244. Effects of mistletoe (Viscum album L.) extracts Iscador on cell cycle and survival of tumor cells. Arzneimittelforschung, 2006
  245. Cytostatic and cytocidal effects of mistletoe (Viscum album L.) quercus extract Iscador. Arzneimittelforschung, 2006
  246. Nitric oxide involvement in the anti-tumor effect of mistletoe (Viscum album L.) extracts Iscador on human macrophages. Arzneimittelforschung, 2006
  247. Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (Viscum album L.) extracts Iscador in vitro. Arzneimittelforschung, 2006
  248. Antiproliferative effects of mistletoe (Viscum album L.) extract in urinary bladder carcinoma cell lines. Anticancer Res, 2006
  249. Glycosyldisulfides from dynamic combinatorial libraries as O-glycoside mimetics for plant and endogenous lectins: their reactivities in solid-phase and cell assays and conformational analysis by molecular dynamics simulations. Bioorg Med Chem, 2006
  250. Alternative medicine remedies might stimulate viability of leukemic cells. Pediatr Blood Cancer, 2006
  251. Exploratory study on the effects of treatment with two mistletoe preparations on chronic hepatitis C. Arzneimittelforschung, 2005
  252. Viscum album agglutinin-I (VAA-I) induces apoptosis and degradation of cytoskeletal proteins in human leukemia PLB-985 and X-CGD cells via caspases: lamin B1 is a novel target of VAA-I. Leuk Res, 2005
  253. [Unconventional cancer therapies--comparisons of attitudes and knowledge between physicians in Germany and Greece]. Forsch Komplementarmed Klass Naturheilkd, 2005
  254. The Viscum album extract Iscador P does not cause an autocrine interleukin-6 loop in B-Non-Hodgkin's Lymphoma cell lines. Onkologie, 2005
  255. Interleukin-6-mediated cell growth in multiple myeloma--a role for Viscum album extracts? Onkologie, 2005
  256. Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. Anticancer Res, 2005
  257. Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung. Anticancer Res, 2005
  258. Viscum album agglutinin-I induces apoptosis and degradation of cytoskeletal proteins via caspases in human leukaemia eosinophil AML14.3D10 cells: differences with purified human eosinophils. Br J Haematol, 2005
  259. Monomer/dimer equilibrium of the AB-type lectin from mistletoe enables combination of toxin/agglutinin activities in one protein: analysis of native and citraconylated proteins by ultracentrifugation/gel filtration and cell biological consequences of dimer destabilization. Glycobiology, 2005
  260. Human cancer cells exhibit in vitro individual receptiveness towards different mistletoe extracts. Pharmazie, 2005
  261. Cloning and expression of mistletoe lectin III B-subunit. Biochemistry (Mosc), 2005
  262. [Studies on the anticancer effects of total alkaloid from Viscum coloratum]. Zhongguo Zhong Yao Za Zhi, 2005
  263. Apoptosis inducing activity of viscin, a lipophilic extract from Viscum album L. J Pharm Pharmacol, 2005
  264. Influence of mistletoe lectins and cytokines induced by them on cell proliferation of human melanoma cells in vitro. Toxicology, 2005
  265. Differential effects of Viscum album extract IscadorQu on cell cycle progression and apoptosis in cancer cells. Int J Oncol, 2004
  266. [The most recent research results confirm the safety and effectiveness of iscador in cancer]. Krankenpfl J, 2004
  267. Isolation of epi-oleanolic acid from Korean mistletoe and its apoptosis-lnducing activity in tumor cells. Arch Pharm Res, 2004
  268. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem Biophys Res Commun, 2004
  269. Critical role of reactive oxygen species and mitochondrial membrane potential in Korean mistletoe lectin-induced apoptosis in human hepatocarcinoma cells. Mol Pharmacol, 2004
  270. Demonstration of antibodies to the chitin-binding mistletoe lectin (cbML) in tumor patients before and during therapy with an aqueous mistletoe extract. Eur J Med Res, 2004
  271. [Added to conventional therapy, what does mistletoe extract contribute in breast carcinoma]. MMW Fortschr Med, 2004
  272. DDI-microFIA--A readily configurable microarray-fluorescence immunoassay based on DNA-directed immobilization of proteins. Chembiochem, 2004
  273. Effects of Viscum album extract therapy in patients with cancer: relation with interleukin-6, soluble interleukin-6 receptor, and soluble gp130. J Altern Complement Med, 2004
  274. Impact of mistletoe lectin binding in breast cancer. Anticancer Res, 2004
  275. Preparation of alginate/chitosan microcapsules and enteric coated granules of mistletoe lectin. Arch Pharm Res, 2004
  276. Mistletoe lectin induces apoptosis and telomerase inhibition in human A253 cancer cells through dephosphorylation of Akt. Arch Pharm Res, 2004
  277. Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway. Eur J Cancer, 2004
  278. Persubstituted cyclodextrin-based glycoclusters as inhibitors of protein-carbohydrate recognition using purified plant and mammalian lectins and wild-type and lectin-gene-transfected tumor cells as targets. Bioconjug Chem, 2004
  279. Mistletoe and gemcitabine in patients with advanced cancer: a model for the phase I study of botanicals and botanical-drug interactions in cancer therapy. Integr Cancer Ther, 2003
  280. [Use of complementary/alternative therapy methods by patients with breast cancer]. Forsch Komplementarmed Klass Naturheilkd, 2003
  281. No evidence of stimulation of human tumor cell proliferation by a standardized aqueous mistletoe extract in vitro. Anticancer Res, 2003
  282. First demonstration of differential inhibition of lectin binding by synthetic tri- and tetravalent glycoclusters from cross-coupling of rigidified 2-propynyl lactoside. Org Biomol Chem, 2003
  283. How does interleukin-6 affect the membrane expressions of interleukin-6 receptor and gp130 and the proliferation of the human myeloma cell line OPM-2? Biomed Pharmacother, 2003
  284. NMR solution structure of viscotoxin C1 from Viscum album species Coloratum ohwi: toward a structure-function analysis of viscotoxins. Biochemistry, 2003
  285. Involvement of hydrogen peroxide in mistletoe lectin-II-induced apoptosis of myeloleukemic U937 cells. Life Sci, 2003
  286. Cytokine release of whole blood from adult female donors challenged with mistletoe lectin-1 standardised mistletoe extract and E. coli endotoxin or phytohaemagglutinin (PHA). Anticancer Res, 2003
  287. Use of alternative medicine by patients with cancer in a rural area of Switzerland. Swiss Med Wkly, 2003
  288. [Iscador--alternative medicine?]. Tidsskr Nor Laegeforen, 2003
  289. Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation. Br J Cancer, 2003
  290. Comparative membrane interaction study of viscotoxins A3, A2 and B from mistletoe (Viscum album) and connections with their structures. Biochem J, 2003
  291. Mistletoe compound enters clinical trials. Drug Discov Today, 2003
  292. Current understanding of mistletoe lectins. Drug Discov Today, 2003
  293. Cytokine release of a keratinocyte model after incubation with two different Viscum album L extracts. Am J Ther, 2003
  294. Synergism between lectins and vesicles of Viscum album L.- detection by biochemical and immunological methods. J Herb Pharmacother, 2002
  295. Cancer therapy with mistletoe:hope or hype? J Herb Pharmacother, 2002
  296. Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. Anticancer Res, 2002
  297. Mistletoe lectins: telomerase inhibitors in alternative cancer therapy. Drug Discov Today, 2002
  298. Induction of apoptosis of endothelial cells by Viscum album: a role for anti-tumoral properties of mistletoe lectins. Mol Med, 2002
  299. [Lectin compared to mistletoe use: experimental therapy form with preclinically verified risk potential]. Dtsch Med Wochenschr, 2002
  300. Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression. Cancer Lett, 2002
  301. Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract. Eur J Med Res, 2002
  302. Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally alpha2-6-sialylated neolacto-series gangliosides. Glycobiology, 2002
  303. Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity. Eur J Biochem, 2002
  304. Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs, 2002
  305. The in vitro effect of Viscum album (VA) extract on DNA repair of peripheral blood mononuclear cells (PBMC) in cancer patients. Phytother Res, 2002
  306. Korean mistletoe lectin-induced apoptosis in hepatocarcinoma cells is associated with inhibition of telomerase via mitochondrial controlled pathway independent of p53. Arch Pharm Res, 2002
  307. [Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks]. Dtsch Med Wochenschr, 2002
  308. The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro. Toxicology, 2002
  309. Natural products of plant origin as anticancer agents. Drug News Perspect, 2001
  310. Patients are talking about ... Iscador (mistletoe). Clin J Oncol Nurs, 2001
  311. Changes in immunological characteristics of white blood cells after administration of standardized mistletoe extract. In Vivo, 2001
  312. Mistletoe lectin synergizes with paclitaxel in human SK-hep1 hepatocarcinoma cells. Immunopharmacol Immunotoxicol, 2001
  313. Mistletoe or not mistletoe is still the question. Forsch Komplementarmed Klass Naturheilkd, 2001
  314. [Modification of mistletoe therapy to prevent epithelial tumors?]. Dtsch Med Wochenschr, 2001
  315. Apoptosis induction associated with cell cycle dysregulation by rice bran agglutinin. J Biochem, 2001
  316. Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells. Anticancer Res, 2001
  317. Binding of mistletoe lectins to cutaneous malignant melanoma: implications for prognosis and therapy. Anticancer Res, 2001
  318. Roles of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in apoptosis of human monoblastic leukemia U937 cells by lectin-II isolated from Korean mistletoe. In Vitr Mol Toxicol, 2001
  319. Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro. Arzneimittelforschung, 2001
  320. Studies in mistletoe therapy and cancer: still waiting for the the big step forward. Forsch Komplementarmed Klass Naturheilkd, 2001
  321. A cytotoxic diarylheptanoid from Viscum cruciatum. Phytochemistry, 2001
  322. Variable sensitivity of lymphoblastoid cells to apoptosis induced by Viscum album Qu FrF, a therapeutic preparation of mistletoe lectin. Chemotherapy, 2001
  323. Mistletoe lectin-1 increases tumor necrosis factor-alpha release in lipopolysaccharide-stimulated whole blood via inhibition of interleukin-10 production. J Pharmacol Exp Ther, 2001
  324. [Oncologic mistletoe therapy--physicians' use and estimation of efficiency]. Dtsch Med Wochenschr, 2001
  325. Where are cancer survivors in the Iscador study? Altern Ther Health Med, 2001
  326. Use of alternative/complementary therapy in breast cancer patients--a psychological perspective. Support Care Cancer, 2001
  327. Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest, 2001
  328. Mistletoe for cancer? Eur J Cancer, 2001
  329. Activation of caspase cascades in Korean mistletoe (Viscum album var. coloratum) lectin-II-induced apoptosis of human myeloleukemic U937 cells. Gen Pharmacol, 2000
  330. Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro. J Clin Lab Anal, 2000
  331. [Mistletoe therapy. An alternative cancer treatment]. MMW Fortschr Med, 2000
  332. Potentiation of tumor necrosis factor-alpha-induced apoptosis by mistletoe lectin. Immunopharmacol Immunotoxicol, 2000
  333. Activation of c-Jun N-terminal kinase 1 (JNK1) in mistletoe lectin II-induced apoptosis of human myeloleukemic U937 cells. Biochem Pharmacol, 2000
  334. Intracellular expression of IL-4 and inhibition of IFN-gamma by extracts from European mistletoe is related to induction of apoptosis. Anticancer Res, 2000
  335. Ethnobotanical survey in the Palestinian area: a classification of the healing potential of medicinal plants. J Ethnopharmacol, 2000
  336. Serum levels of IL-12 and the production of IFN-gamma, IL-2 and IL-4 by peripheral blood mononuclear cells (PBMC) in cancer patients treated with Viscum album extract. Biomed Pharmacother, 2000
  337. [Favorable long-term outcome with mistletoe therapy in a patient with centroblastic-centrocytic non hodgkin lymphoma]. Dtsch Med Wochenschr, 2000
  338. Protein kinase A or C modulates the apoptosis induced by lectin II isolated from Korean mistletoe, Viscum album var. Coloratum, in the human leukemic HL-60 cells. Immunopharmacol Immunotoxicol, 2000
  339. Heat shock treatment protects human HL-60 cells from apoptosis induced by lectin II isolated from Korean mistletoe, Visum album var. Coloratum. Immunopharmacol Immunotoxicol, 2000
  340. Toxic proteins from European mistletoe (Viscum album L.): increase of intracellular IL-4 but decrease of IFN-gamma in apoptotic cells. Anticancer Res, 2000
  341. Modulation of mistletoe (Viscum album L.) lectins cytotoxicity by carbohydrates and serum glycoproteins. Arzneimittelforschung, 2000
  342. [Unconventional cancer therapy on trial. Mistletoe preparations: only effective in the test tube?. Interview by Elke Runge]. MMW Fortschr Med, 2000
  343. Australian oncologists' self-reported knowledge and attitudes about non-traditional therapies used by cancer patients. Med J Aust, 2000
  344. [Comment on S. Gabius, H.-J. Gabius: Immune modulating mistletoe therapy by lectin standardization: a double-edged sword?]. Versicherungsmedizin, 2000
  345. Differential binding of toxic lectins from Viscum album L., ML I and ML III, to human lymphocytes. Anticancer Res, 1999
  346. Viscotoxin-free aqueous extracts from European mistletoe (Viscum album L.) stimulate activity of human granulocytes. Anticancer Res, 1999
  347. Release of interleukin-6 in cultured B-chronic lymphocytic leukaemia cells is associated with both activation and cell death via apoptosis. Anticancer Res, 1999
  348. Influence of polysaccharides from Viscum album L. on human lymphocytes, monocytes and granulocytes in vitro. Anticancer Res, 1999
  349. Effects of mistletoe lectin I and ionizing radiation on the glucose and thymidine uptake in tumour cells in vitro. Phytother Res, 1999
  350. [Development of lymphocyte subsets in tumor patients after subcutaneous administration of mistletoe extracts]. Forsch Komplementarmed, 1999
  351. Characterization of recombinant and plant-derived mistletoe lectin and their B-chains. Eur J Biochem, 1999
  352. Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain. Eur J Biochem, 1999
  353. Induction of Fas ligand (CD95L) by the toxic mistletoe lectins in human lymphocytes. Anticancer Res, 1999
  354. Ligands for Viscum album agglutinin and galectin-1 in human lung cancer: is there any prognostic relevance? Acta Histochem, 1999
  355. Cytotoxic effects of the components in heat-treated mistletoe (Viscum album). Cancer Lett, 1999
  356. Thionins from Viscum album L: influence of the viscotoxins on the activation of granulocytes. Anticancer Res, 1999
  357. Characterisation of immunological reactivity of patients with adverse effects during therapy with an aqueous mistletoe extract. Eur J Med Res, 1999
  358. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res, 1999
  359. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res, 1999
  360. Lectins isolated from Korean mistletoe (Viscum album coloratum) induce apoptosis in tumor cells. Cancer Lett, 1999
  361. Crystal structure of mistletoe lectin I from Viscum album. Biochem Biophys Res Commun, 1999
  362. Recognition of different antigens of mistletoe extracts by anti-mistletoe lectin antibodies. Cancer Lett, 1999
  363. NO-dependent regulation of lectin- and menadione-induced H2O2 production by cells from pleural effusions of lung cancer patients and by immune cells. Int J Oncol, 1999
  364. Iscador update: interview with Robert Gorter, M.D. Interview by Fred Gardner. AIDS Treat News, 1998
  365. Comparison of the effects of Viscum album lectin ML-1 and fresh plant extract (Isorel) on the cell growth in vitro and tumorigenicity of melanoma B16F10. Cancer Biother Radiopharm, 1998
  366. [Value of mistletoe therapy in carcinoma patients]. Internist (Berl), 1998
  367. Comparison of the effects of various clinically applied mistletoe preparations on peripheral blood leukocytes. Arzneimittelforschung, 1998
  368. Generation of reactive oxygen intermediates (ROI) by the thionins from Viscum album L. Anticancer Res, 1998
  369. Mistletoe in immunology and the clinic (short review). Anticancer Res, 1998
  370. Induction of apoptosis by the N-acetyl-galactosamine-specific toxic lectin from Viscum album L. is associated with a decrease of nuclear p53 and Bcl-2 proteins and induction of telomeric associations. Cancer Lett, 1998
  371. Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity. Immunopharmacol Immunotoxicol, 1998
  372. Prophylactic effect of Korean mistletoe (Viscum album coloratum) extract on tumor metastasis is mediated by enhancement of NK cell activity. Int J Immunopharmacol, 1998
  373. [Use of alternative medicine in oncology patients]. Dtsch Med Wochenschr, 1998
  374. Effects of the Turkish subspecies of Viscum album on macrophage-derived cytokines. J Ethnopharmacol, 1998
  375. Lectin-induced increase in clonogenic growth of haematopoietic progenitor cells. Eur J Haematol, 1998
  376. Effects of mistletoe lectin I on human blood cell lines and peripheral blood cells. Cytotoxicity, apoptosis and induction of cytokines. Arzneimittelforschung, 1997
  377. Green tea, mistletoe, and more: Canadians test alternative cancer therapies. J Natl Cancer Inst, 1997
  378. Oligoclonal in vitro response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients. Cancer Immunol Immunother, 1997
  379. Donor-dependent and dose-dependent variation in the induction of T lymphocyte locomotion in a three-dimensional collagen matrix system by a mistletoe preparation (Iscador). Anticancer Drugs, 1997
  380. Immunomodulatory effects of Viscum album agglutinin-I on natural immunity. Anticancer Drugs, 1997
  381. Mistletoe extract-induced effects on immunocompetent cells: in vitro studies. Anticancer Drugs, 1997
  382. Genotoxicity testing of an aqueous mistletoe extract in vitro. Arzneimittelforschung, 1997
  383. Extracts from Viscum and Crataegus are cytotoxic against larynx cancer cells. Z Naturforsch C J Biosci, 1997
  384. Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes. Cancer Lett, 1996
  385. [The mistletoe myth--claims, reality and provable perspectives]. Z Arztl Fortbild (Jena), 1996
  386. Binding capacities of two immunomodulatory lectins, carrier-immobilized glycoligands and steroid hormones in lung cancer and the concentration of nitrite/nitrate in pleural effusions. Lung Cancer, 1996
  387. Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Cancer Lett, 1996
  388. Complementary therapies in cancer care: an NHS approach. Int J Palliat Nurs, 1996
  389. Release of cytokines by a fermented lectin-1 (ML-1) free mistletoe extract reflects differences in the reactivity of PBMC in healthy and allergic individuals and tumour patients. Eur J Clin Pharmacol, 1996
  390. Unconventional cancer therapy--survey of patients with gynaecological malignancy. Arch Gynecol Obstet, 1996
  391. A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun, 1995
  392. Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett, 1995
  393. Biochemical, histochemical and cell biological investigations on the actions of mistletoe lectins I, II and III with human breast cancer cell lines. Glycoconj J, 1995
  394. Expression of lectin, interleukin-2 and histopathologic blood group binding sites in prostate cancer and its correlation with integrated optical density and syntactic structure analysis. Anal Quant Cytol Histol, 1995
  395. Carbohydrate-binding proteins (plant/human lectins and autoantibodies from human serum) as mediators of release of lysozyme, elastase, and myeloperoxidase from human neutrophils. Res Exp Med (Berl), 1995
  396. Are matrix-immobilized neoglycoproteins, plant and human lectins and carbohydrate--binding antibodies from human serum mediators of adhesion in vitro for carcinoma and lymphosarcoma cells? Anticancer Res, 1995
  397. Viscum album agglutinin-induced aggregation of blood cells and the lectin effects on neutrophil function. Biomed Pharmacother, 1995
  398. Expression of galactoside-specific endogenous lectins and their ligands in human oral squamous cell carcinoma. Cancer Lett, 1994
  399. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res, 1994
  400. In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung, 1993
  401. Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel. Oncology, 1993
  402. Modulation of lectin-triggered superoxide release from neutrophils of tumor patients with and without chemotherapy. Anticancer Res, 1993
  403. [Mistletoe in the treatment of cancer]. Tidsskr Nor Laegeforen, 1993
  404. [Effect of mistletoe lectin therapy on serum level of defined serum proteins (acute phase proteins) in tumor patients]. Med Klin (Munich), 1993
  405. [Comparative studies on the immunoactive action of galactoside-specific mistletoe lectin. Pure substance compared to the standardized extract]. Arzneimittelforschung, 1993
  406. Mechanism of stimulation of human natural killer cytotoxicity by arabinogalactan from Larix occidentalis. Cancer Immunol Immunother, 1993
  407. The galactoside-specific lectin from mistletoe as biological response modifier. Int J Oncol, 1992
  408. Identity of the N-terminal sequences of the three A chains of mistletoe (Viscum album L.) lectins: homology with ricin-like plant toxins and single-chain ribosome-inhibiting proteins. Anticancer Drugs, 1992
  409. Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients. Clin Investig, 1992
  410. The immunomodulatory beta-galactoside-specific lectin from mistletoe: partial sequence analysis, cell and tissue binding, and impact on intracellular biosignalling of monocytic leukemia cells. Anticancer Res, 1992
  411. Analysis of tumour necrosis factor alpha-specific, lactose-specific and mistletoe lectin-specific binding sites in human lung carcinomas by labelled ligands. Virchows Arch A Pathol Anat Histopathol, 1992
  412. Study of the activities of Chinese herb Viscum alniformosanae Part II: The components of conditioned medium produced by Viscum alniformosanae-stimulated mononuclear cells. Am J Chin Med, 1992
  413. [Why do cancer patients use alternative medicine?]. Schweiz Med Wochenschr, 1991
  414. Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (Viscum album L.). Klin Wochenschr, 1991
  415. Induction of tumor necrosis factor expression by a lectin from Viscum album. Cancer Immunol Immunother, 1991
  416. Study of the activity of differentiation-induction in a Chinese herb-viscum alniformosanae. Part 1: In vitro induction of differentiation in HL-60 leukemic cell line by conditioned medium secreted from viscum alniformosanae-stimulated mononuclear cells. Am J Chin Med, 1991
  417. Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro. Klin Wochenschr, 1990
  418. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition. Cancer Res, 1990
  419. [In vitro studies of the effect of a mistletoe preparation on melanoma cells]. Z Hautkr, 1990
  420. Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res, 1990
  421. Characterization of cytotoxic proteins from mistletoe (Viscum album L.). Cancer Lett, 1990
  422. [Iscucin--mistletoe preparations for the pre- and postoperative treatment of malignancies. Documentation No. 21]. Schweiz Rundsch Med Prax, 1990
  423. Chemical specificity of effector cell/tumor cell bridging by a Viscum album rhamnogalacturonan enhancing cytotoxicity of human NK cells. Immunopharmacology, 1990
  424. Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from viscum album extract. Arzneimittelforschung, 1989
  425. Influence of Viscum album preparations on the natural killer cell-mediated cytotoxicity of peripheral blood. Naturwissenschaften, 1989
  426. Mistletoe in homoeopathic cancer treatment. Prof Nurse, 1989
  427. [Immunomodulation by leukocytolysis. On the significance of lectin-polysaccharide complexes]. Onkologie, 1989
  428. [Anthroposophy. Mistletoe preparations: a cancer inhibiting wonder drug?]. Krankenpfl Soins Infirm, 1989
  429. [Are paramedical means and methods justified in the treatment of breast carcinoma?]. Schweiz Rundsch Med Prax, 1989
  430. Biochemical characterization of a component in extracts of Viscum album enhancing human NK cytotoxicity. Immunopharmacology, 1989
  431. [Mistletoe therapy of metastasizing renal cancer. A phase II study]. Ugeskr Laeger, 1988
  432. Characterization of a toxic lectin in Iscador, a mistletoe preparation with alleged cancerostatic properties. Oncology, 1988
  433. [Alternative medicine in oncology]. Z Gesamte Inn Med, 1987
  434. Assay of the cell-mediated immunity in patients with malignant and non-malignant diseases. Onkologie, 1987
  435. Effects of lectin I from mistletoe (ML I) and its isolated A and B chains on human mononuclear cells: mitogenic activity and lymphokine release. Pharmazie, 1987
  436. In vitro effectiveness of a mistletoe preparation on cytostatic-drug-resistant human leukemia cells. Naturwissenschaften, 1987
  437. [Possibilities and limits of mistletoe therapy in cancer patients]. Arch Gynecol Obstet, 1987
  438. Mediation of human NK-activity by components in extracts of Viscum album. Int J Immunopharmacol, 1987
  439. Effects of mistletoe (Viscum album L.) extracts on cultured tumor cells. Experientia, 1986
  440. Differences in the in vitro effectiveness of preparations produced from mistletoes of various host trees. Arzneimittelforschung, 1986
  441. [The use of paramedical treatment methods by cancer patients. A inquiry on 101 ambulatory patients]. Dtsch Med Wochenschr, 1986
  442. Natural killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients. Oncology, 1986
  443. Structure and properties of polysaccharides from Viscum album (L.). Oncology, 1986
  444. Pleura carcinosis. Cytomorphological findings with the mistletoe preparation iscador and other pharmaceuticals. Oncology, 1986
  445. Comparison of the effects of fermented and unfermented mistletoe preparations on cultured tumor cells. Oncology, 1986
  446. Immunomodulatory effects of iscador: a Viscum album preparation. Oncology, 1986
  447. Are lectins of Viscum album interesting tools in lung diseases? A review of recent results. Z Erkr Atmungsorgane, 1986
  448. [Ingredients of mistletoe (Viscum album L.) as potential drugs]. Pharmazie, 1985
  449. [Value of the lymphocyte transformation test for determining immune status]. Dermatologica, 1985
  450. Immunological reactivity of tumor associated glycoproteins prepared by affinity chromatography. Arch Geschwulstforsch, 1984
  451. Iscador. CA Cancer J Clin, 1983
  452. Action of viscumin, a toxic lectin from mistletoe, on cells in culture. J Biol Chem, 1982
  453. [Extracts of mistletoe in cancer therapy]. Ugeskr Laeger, 1982
  454. The influence of a mistletoe preparation on suspension cell cultures of human leukemia and human myeloma cells. Arzneimittelforschung, 1982
  455. [Mistletoe therapy in modern cancer treatment?]. ZFA (Stuttgart), 1981
  456. [Mistletoe therapy of breast cancer in comparison with chemotherapy and radiotherapy]. ZFA (Stuttgart), 1981
  457. [Adjuvant mistletoe therapy in cancer. Experiences at the Ludwig-Boltzmann Institute for Clinical Oncology]. ZFA (Stuttgart), 1981
  458. [The possibilities of mistletoe therapy in cancer]. ZFA (Stuttgart), 1981
  459. [Treatment of breast cancer. A comparison between postoperative radiotherapy and long-term iscador treatment following conservative radical mastectomy]. Med Welt, 1980
  460. Isolation of viscotoxins. Cytotoxic basic polypeptides from Viscum album L. Hoppe Seylers Z Physiol Chem, 1980
  461. Combination of immunological and lectin reactions in affinity histochemistry: proposition of the term affinitin. Histochemistry, 1979
  462. [Use of ferritin conjugates of a lectin from mistletoe (Viscum album L.) for the electron microscopic localization of cell surface receptors]. Acta Biol Med Ger, 1978
  463. [Postoperative Viscum album therapy after surgery of breast neoplasms]. Helv Chir Acta, 1977
  464. Isolation and characterization of mistletoe extracts (Viscum album L.). I. Affinity chromatography of mistletoe extracts on immobilized plasma proteins. Acta Biol Med Ger, 1977
  465. [Mistletoe therapy--physicians warned. No acceptable ground for cancer diagnosis]. Lakartidningen, 1975
  466. [Investigation to improve the survival of patients with bronchial carcinomas "radically operated" (author's transl)]. Z Erkr Atmungsorgane, 1975
  467. [Life expectancy of patients with resected bronchial carcinoma and postoperative cytostatic therapy using trenimon, cealysin, and viscum album]. Pneumonologie, 1973
  468. [Callus cultures from Viscum album. A possible source of raw materials for gaining therapeutic interesting extracts]. Planta Med, 1971
  469. [Viscum album in the treatment of neoplasms]. Ther Ggw, 1971
  470. Heterophile agglutinins with a broad-spectrum specificity. VI. The nature of cell surface receptors for the agglutinins present in seeds of Amaranthus caudatus, Maclura aurantica, Datura stramonium, Viscum album, Phaseolus vulgaris and Moluccella laevis. Z Immunitatsforsch Allerg Klin Immunol, 1970
  471. [Studies on additional Iscador therapy in the management of women with surgically and radiotherapeutically treated genital carcinoma]. Gynaecologia, 1969
  472. [Iscador]. Duodecim, 1968
  473. [Is mistletoe an old cancer remedy?]. Sudhoffs Arch Gesch Med Naturwiss, 1965
  474. [STIMULATION OF NEUTROPHILIA BY A POLYSACCHARIDE EXTRACT OF "VISCUM ALBUM". ITS THERAPEUTIC USE IN NEUTROPENIA]. Rev Fr Etud Clin Biol, 1963
  475. [On the knowledge of tumor growth-inhibiting principle of mistletoe (Viscum album L.)]. Arzneimittelforschung, 1963
  476. [Experiences with the decrease in radical operation and Iscador follow-up treatment of breast carcinoma]. Krebsarzt, 1962
  477. [On the identification of the constituents of Viscum album. II. Tumor inhibiting substances]. Hoppe Seylers Z Physiol Chem, 1961
  478. [Mistletoe therapy in cancer without "heroic" precautions]. Heilkd Heilwege, 1961
  479. [Viscotherapy of cancer. Philosophical bases and clinical aspects. Criticism]. Arq Patol, 1960
  480. [Histopathological studies on cancers previously treated with iscador]. Zentralbl Allg Pathol, 1960
  481. [Successful treatment of a cervix carcinoma of malignant appearance]. Ther Ggw, 1959
  482. [Treatment of malignant tumors of the bladder with Viscum album]. Z Urol, 1958
  483. [Results of management of inoperable female genital carcinoma with plenosol for a period of 5 years]. Medizinische, 1956
  484. [Plenosol therapy of carcinoma in general practice]. Hippokrates, 1954
  485. [First attempts with plenosol therapy in inoperable bladder carcinoma]. Z Urol, 1954
  486. [Mistletoe extract and vitamin A in the treatment of carcinoma of the female genitalia]. Zentralbl Gynakol, 1954
  487. [Viscum album extract in therapy of advanced cancer]. Belg Tijdschr Geneesk, 1953
  488. [The effect of plenosol on recurrent cervical and breast carcinoma]. Ther Ggw, 1952
  489. [Viscum album therapy in tumors of the bladder]. Hippokrates, 1952
  490. [The mistletoe extract plenosol postoperation or postradiation therapy of cervical cancer]. Zentralbl Gynakol, 1952
  491. [Once again: viscum therapy of carcinoma; open letter to Dr. D. Brück]. Hippokrates, 1951
Reviews 86
  1. Mistletoe in Cancer Cell Biology: Recent Advances. Curr Issues Mol Biol, 2025
  2. The Promising Role of Plant-Derived Lectins in Oral Cancer Therapeutics: A Systematic Review. Cureus, 2024
  3. Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid Tumours. Curr Oncol Rep, 2024
  4. Viscum album (mistletoe) extract for dogs with cancer? Front Vet Sci, 2023
  5. The Anti-Inflammatory Activity of Viscum album. Plants (Basel), 2023
  6. Are Aspects of Integrative Concepts Helpful to Improve Pancreatic Cancer Therapy? Cancers (Basel), 2023
  7. Horner's Syndrome and Lymphocele Following Thyroid Surgery. J Clin Med, 2023
  8. [Phytotherapy in uro-oncology]. Urologie, 2023
  9. Plant lectin: A promising future anti-tumor drug. Biochimie, 2022
  10. Cancer Chemotherapy via Natural Bioactive Compounds. Curr Drug Discov Technol, 2022
  11. Viscum album L. Therapy in Oncology: An Update on Current Evidence. Complement Med Res, 2022
  12. The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: A narrative review. J Clin Transl Res, 2021
  13. Exploring the resources of the genus Viscum for potential therapeutic applications. J Ethnopharmacol, 2021
  14. Plant-made immunotoxin building blocks: A roadmap for producing therapeutic antibody-toxin fusions. Biotechnol Adv, 2021
  15. Nutritional traditional and complementary medicine strategies in pediatric cancer: A narrative review. Pediatr Blood Cancer, 2020
  16. [Mistletoe in the treatment of cancer patients]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2020
  17. Anticancer Effects of Herbal Medicine Compounds and Novel Formulations: a Literature Review. J Gastrointest Cancer, 2020
  18. Therapeutic Potential of Medicinal Plant Proteins: Present Status and Future Perspectives. Curr Protein Pept Sci, 2020
  19. Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies. Evid Based Complement Alternat Med, 2019
  20. Do recent research studies validate the medicinal plants used in British Columbia, Canada for pet diseases and wild animals taken into temporary care? J Ethnopharmacol, 2019
  21. Viscum articulatum Burm. f.: a review on its phytochemistry, pharmacology and traditional uses. J Pharm Pharmacol, 2018
  22. A Hidden Treasure: The Borneo Mistletoes. Pharmacogn Rev, 2017
  23. Fever: Views in Anthroposophic Medicine and Their Scientific Validity. Evid Based Complement Alternat Med, 2016
  24. Coley's Lessons Remembered: Augmenting Mistletoe Therapy. Integr Cancer Ther, 2016
  25. Phytochemical profile and therapeutic potential of Viscum album L. Nat Prod Res, 2016
  26. Natural products are the future of anticancer therapy: Preclinical and clinical advancements of Viscum album phytometabolites. Cell Mol Biol (Noisy-le-grand), 2015
  27. Cancer therapy with phytochemicals: evidence from clinical studies. Avicenna J Phytomed, 2015
  28. Lectins with potential for anti-cancer therapy. Molecules, 2015
  29. [Immunostimulatory properties of mistletoe extracts and their application in oncology]. Postepy Hig Med Dosw (Online), 2014
  30. Preclinical and clinical effects of mistletoe against breast cancer. Biomed Res Int, 2014
  31. Bioactive proteins and peptides isolated from Chinese medicines with pharmaceutical potential. Chin Med, 2014
  32. Complementary and alternative medicine for cancer pain: an overview of systematic reviews. Evid Based Complement Alternat Med, 2014
  33. Could plant lectins become promising anti-tumour drugs for causing autophagic cell death? Cell Prolif, 2013
  34. Adverse effects of herbal medicines: an overview of systematic reviews. Clin Med (Lond), 2013
  35. [Mistletoe extract for treatment of urological tumors]. Urologe A, 2012
  36. The use of herbal medicine in cancer-related anorexia/ cachexia treatment around the world. Curr Pharm Des, 2012
  37. Plant lectins: targeting programmed cell death pathways as antitumor agents. Int J Biochem Cell Biol, 2011
  38. The preclinical and clinical activity of aviscumine: a potential anticancer drug. Eur J Cancer, 2011
  39. Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions. Leuk Lymphoma, 2010
  40. Immunomodulatory effects of Viscum album extracts on natural killer cells: review of clinical trials. Forsch Komplementmed, 2010
  41. Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem, 2010
  42. Clinical research in anthroposophic medicine. Altern Ther Health Med, 2009
  43. [Complementary medicine in oncology]. Urologe A, 2009
  44. Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med, 2009
  45. [A critical assessment of phytotherapy for prostate cancer]. Urologe A, 2009
  46. [Possible application of lectins in diagnostics and therapy. Part I. Diagnostic application]. Przegl Lek, 2008
  47. Uses of plant lectins in bioscience and biomedicine. Front Biosci, 2008
  48. A critical review of complementary therapies for cancer-related fatigue. Integr Cancer Ther, 2007
  49. Preclinical investigations with mistletoe (Viscum album L.) extract Iscador. Arzneimittelforschung, 2006
  50. Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung, 2006
  51. Developmental therapeutics: review of biologically based CAM therapies for potential application in children with cancer: part I. J Pediatr Hematol Oncol, 2006
  52. Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins. Histol Histopathol, 2006
  53. Comparison of the impact of pro- and antiinflammatory immune processes at the two immune-deviated sites, eye and solid tumor and possible consequences for the antitumoral therapy with fever inducers. Forsch Komplementarmed Klass Naturheilkd, 2005
  54. Botanical medicine and cancer: a review of the safety and efficacy. Expert Opin Pharmacother, 2004
  55. Mistletoe and cancer: controversies and perspectives. Semin Oncol, 2002
  56. Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials. Cancer Invest, 2002
  57. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie, 2002
  58. Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research. Anticancer Res, 2002
  59. Dietary mistletoe lectin supplementation and reduced growth of a murine non-Hodgkin lymphoma. Histol Histopathol, 2002
  60. Probing the cons and pros of lectin-induced immunomodulation: case studies for the mistletoe lectin and galectin-1. Biochimie, 2001
  61. [Does mistletoe therapy influence the defense against epithelial tumors? A critical immunologic analysis]. Dtsch Med Wochenschr, 2001
  62. A primer of complementary and alternative medicine commonly used by cancer patients. Med J Aust, 2001
  63. Therapeutic applications of medicinal plants in the treatment of breast cancer: a review of their pharmacology, efficacy and tolerability. Adverse Drug React Toxicol Rev, 2000
  64. Modulation of programmed cell death by medicinal plants. Cell Mol Biol (Noisy-le-grand), 2000
  65. Unproven methods in cancer: a worldwide problem. Support Care Cancer, 2000
  66. Counseling cancer patients about herbal medicine. Patient Educ Couns, 1999
  67. How useful are unconventional cancer treatments? Eur J Cancer, 1999
  68. [Mistletoe therapy from the pharmacologic perspective]. Forsch Komplementarmed, 1999
  69. [Immunomodulating mistletoe therapy by lectin standardization: a double-edged sword?]. Versicherungsmedizin, 1999
  70. [Value of mistletoe lectin standardized mistletoe extract for evaluating antitumor properties]. Wien Med Wochenschr, 1999
  71. Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ, 1998
  72. Unconventional therapies for cancer: 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ, 1998
  73. Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts. Anticancer Drugs, 1997
  74. Mistletoe therapy for human cancer: the role of the natural killer cells. Anticancer Drugs, 1997
  75. Stimulation of the specific immune system by mistletoe extracts. Anticancer Drugs, 1997
  76. Differences in the apoptosis-inducing properties of Viscum album L. extracts. Anticancer Drugs, 1997
  77. Modulation of cytotoxicity and enhancement of cytokine release induced by Viscum album L. extracts or mistletoe lectins. Anticancer Drugs, 1997
  78. From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe? Planta Med, 1994
  79. Unproven methods in cancer treatment. Curr Opin Oncol, 1993
  80. [Mistletoe in the treatment of cancer]. Tidsskr Nor Laegeforen, 1993
  81. Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review. J Biol Regul Homeost Agents, 1993
  82. Reflections on cancer therapy. Mater Med Pol, 1991
  83. [Immune modulators in the treatment of malignant melanoma]. Fortschr Med, 1989
  84. Recent studies on the anticancer activities of mistletoe (Viscum album) and its alkaloids. Oncology, 1986
  85. Mistletoe lectins and their A and B chains. Oncology, 1986
  86. Viscum album--a possible treatment for cancer? Bristol Med Chir J, 1973
Other papers, not yet read by us 212
  1. Mistletoe extract (Iscador®) in cancer patients undergoing chemotherapy for prostate and bladder tumors: A prospective observational study. Avicenna J Phytomed, 2026
  2. Efficacy and Safety of Viscum album L. in Patients With Triple-Negative Breast Cancer Receiving Immune Checkpoint Inhibitors: A Protocol for an Open-Label Randomized Clinical Trial. Integr Cancer Ther, 2026
  3. An integrative naturopathic oncology approach in metastatic malignant melanoma: two case reports. Front Oncol, 2026
  4. Mistletoe extract in patients with advanced pancreatic cancer: Health-related quality of life in a double-blind, randomized, placebo-controlled trial (MISTRAL). Palliat Med, 2026
  5. Integrative Oncology Approach in Advanced Myxofibrosarcoma: A Case Report of Prolonged Survival with High-Dose Vitamin C and Viscum album. Case Rep Oncol, 2026
  6. MISTOSUS: a phase II trial of Viscum album extract adjuvant therapy for relapsed resectable osteosarcoma. Future Oncol, 2026
  7. Beyond Viscum album: Mistletoe physiology and the pharmacological potential of the extensive Loranthaceae family. J Ethnopharmacol, 2026
  8. Systematic review and network meta-analysis of the effects of plant active substance on quality of life in breast cancer patients. Front Pharmacol, 2025
  9. The Mistletoe and Breast Cancer (MAB) Study: A UK Mixed-Phase, Pilot, Placebo-Controlled, Double-Blind, Randomised Controlled Trial. Cancers (Basel), 2025
  10. Unconventional Treatments for Pancreatic Cancer: A Systematic Review. Cancers (Basel), 2025
  11. Combined Immune Checkpoint Blockade and Helixor® Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW). Int J Mol Sci, 2025
  12. Nonintravesical Interventions for Preventing Intravesical Recurrence in Patients With Nonmuscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer, 2025
  13. ER+ HER2- Invasive Breast Cancer: Tumor Remission following Viscum Album Extract/Influenza Vaccine Treatment - A Report of 2 Cases. Complement Med Res, 2025
  14. Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence. Pharmaceuticals (Basel), 2024
  15. Immunomodulatory Activity and Inhibitory Effects of Viscum album on Cancer Cells, Its Safety Profiles and Recent Nanotechnology Development. Planta Med, 2024
  16. Viscum Album Lipophilic Extract in Actinic Keratosis, Cutaneous Squamous Cell Carcinoma, and Basal Cell Carcinoma: A Retrospective Case Series. Complement Med Res, 2024
  17. Clinical characteristics and therapeutic behavior of breast cancer patients using mistletoe therapy consulting a clinic offering integrative oncology: a registry data analysis. BMC Complement Med Ther, 2023
  18. Quality of Life in Breast Cancer Patients Treated With Mistletoe Extracts: A Systematic Review and Meta-Analysis. Integr Cancer Ther, 2023
  19. Patient' and social aspects related to complementary mistletoe therapy in patients with breast cancer: A systematic review commissioned by the German agency for Health Technology Assessment. Eur J Oncol Nurs, 2023
  20. Utilization of complementary and alternative medicine (CAM) by women with breast cancer or gynecological cancer. PLoS One, 2023
  21. Mistletoe for Bladder Cancer: Call for More Case Reports Using the Intravesical Route. Altern Ther Health Med, 2023
  22. Evaluation of quality of life in lung cancer patients receiving radiation and Viscum album L.: a real-world data study. Radiat Oncol, 2023
  23. Safety of Combined Targeted and Helixor®Viscum album L. Therapy in Breast and Gynecological Cancer Patients, a Real-World Data Study. Int J Environ Res Public Health, 2023
  24. Systematic analysis of mistletoe prescriptions in clinical studies. J Cancer Res Clin Oncol, 2023
  25. Drug Interactions Causing Warfarin Overdose in a Patient with Pancreatic Cancer: A Case Report. Chemotherapy, 2023
  26. Meta-Analysis of Pharmacological, Nutraceutical and Phytopharmaceutical Interventions for the Treatment of Cancer Related Fatigue. Cancers (Basel), 2022
  27. Additional treatment with mistletoe extracts for patients with breast cancer compared to conventional cancer therapy alone - efficacy and safety, costs and cost-effectiveness, patients and social aspects, and ethical assessment. Ger Med Sci, 2022
  28. Viscum album L., a Therapeutic Option for Neoplastic Diseases in Companion Animals? A Systematic Review. Complement Med Res, 2022
  29. Integrative medicine during the intensive phase of chemotherapy in pediatric oncology in Germany: a randomized controlled trial with 5-year follow up. BMC Cancer, 2022
  30. Cancer-related fatigue in patients treated with mistletoe extracts: a systematic review and meta-analysis. Support Care Cancer, 2022
  31. The Potential Role of Korean Mistletoe Extract as an Anti-Inflammatory Supplementation. J Immunol Res, 2021
  32. Effect of mistletoe extract on tumor response in neoadjuvant chemoradiotherapy for rectal cancer: a cohort study. World J Surg Oncol, 2021
  33. Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series. Case Rep Oncol, 2021
  34. Viscum album extract (Helixor-M) treatment for thoracic duct injury after modified radical neck dissection: a case report. Gland Surg, 2021
  35. Long-Term Survival of a Patient with Recurrent Dedifferentiated High-Grade Liposarcoma of the Retroperitoneum Under Adjuvant Treatment with Viscum album L. Extract: A Case Report. Integr Cancer Ther, 2021
  36. Analysis of Changes in Cancer-Related Fatigue of Breast Cancer Patients Receiving an Integrative Medicine Program. Integr Cancer Ther, 2020
  37. Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL). Trials, 2020
  38. Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients. PLoS One, 2020
  39. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis. BMC Complement Med Ther, 2020
  40. Reducing Malignant Ascites and Long-Term Survival in a Patient with Recurrent Gastric Cancer Treated with a Combination of Docetaxel and Mistletoe Extract. Case Rep Oncol, 2020
  41. Impact of Oncological Therapy and Viscum album L Treatment on Cancer-Related Fatigue and Internal Coherence in Nonmetastasized Breast Cancer Patients. Integr Cancer Ther, 2020
  42. Cost-Effectiveness of Real-World Administration of Concomitant Viscum album L. Therapy for the Treatment of Stage IV Pancreatic Cancer. Evid Based Complement Alternat Med, 2020
  43. Viscum pleurodesis is as effective as talc pleurodesis and tends to have less adverse effect. Support Care Cancer, 2020
  44. Long-term survival of a patient with an inoperable thymic neuroendocrine tumor stage IIIa under sole treatment with Viscum album extract: A CARE compliant clinical case report. Medicine (Baltimore), 2020
  45. Bilateral Asynchronous Renal Cell Carcinoma With Lung Metastases: A Case Report of a Patient Treated Solely With High-dose Intravenous and Subcutaneous Viscum album Extract for a Second Renal Lesion. Anticancer Res, 2019
  46. Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment with Viscum album extracts: A case report. World J Gastroenterol, 2019
  47. Supportive mistletoe therapy in a patient with metastasised neuroblastoma. BMJ Case Rep, 2019
  48. Chemoimmunotherapy in Advanced Renal Cell Carcinoma: A Case Report of a Long-Term Survivor Adjunctly Treated with Viscum album Extracts. Complement Med Res, 2019
  49. Antiproliferative potential from aqueous Viscum album L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells. J Ethnopharmacol, 2019
  50. Prolonged stabilization of platinum-refractory ovarian cancer in a single patient undergoing long-term Mistletoe extract treatment: Case report. Medicine (Baltimore), 2019
  51. Use and Safety of Viscum album L Applications in Cancer Patients With Preexisting Autoimmune Diseases: Findings From the Network Oncology Study. Integr Cancer Ther, 2019
  52. Mistletoe in oncological treatment: a systematic review : Part 2: quality of life and toxicity of cancer treatment. J Cancer Res Clin Oncol, 2019
  53. Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer. Support Care Cancer, 2019
  54. Long-Term Tumor-Free Survival in a Patient with Stage IV Epithelial Ovarian Cancer Undergoing High-Dose Chemotherapy and Viscum album Extract Treatment: A Case Report. Perm J, 2018
  55. Long-term tumor-free survival in a metastatic pancreatic carcinoma patient with FOLFIRINOX/Mitomycin, high-dose, fever inducing Viscum album extracts and subsequent R0 resection: A case report. Medicine (Baltimore), 2018
  56. Intralesional and subcutaneous application of Viscum album L. (European mistletoe) extract in cervical carcinoma in situ: A CARE compliant case report. Medicine (Baltimore), 2018
  57. Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series. Complement Ther Med, 2018
  58. Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under Viscum album Extracts After Resistance to R-CHOP: A Case Report. Anticancer Res, 2018
  59. Immunological and Quality-of-Life Profiles in Women with Breast Cancer: Complementary versus Conventional Care. Complement Med Res, 2018
  60. Durable clinical remission of a skull metastasis under intralesional Viscum album extract therapy: Case report. Head Neck, 2018
  61. A 21-year course of Merkel cell carcinoma with adjuvant Viscum album extract treatment: A case report. Complement Ther Med, 2018
  62. Chemical Pleurodesis Using Viscum album Extract in Gorham Disease Complicated with Chylothorax. Acute Crit Care, 2018
  63. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations. Integr Cancer Ther, 2018
  64. Pleurodesis Using Mistletoe Extract Delivered via a Spray Catheter during Semirigid Pleuroscopy for Managing Symptomatic Malignant Pleural Effusion. Respiration, 2018
  65. Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report. J Thorac Dis, 2017
  66. Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. BMC Complement Altern Med, 2017
  67. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients. Phytomedicine, 2017
  68. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer. BMC Complement Altern Med, 2017
  69. Chemical pleurodesis using mistletoe extracts via spray catheter during medical thoracoscopy for management of malignant pleural effusion. Respirol Case Rep, 2017
  70. Benefits, pitfalls and risks of phytotherapy in clinical practice in otorhinolaryngology. Eur Ann Otorhinolaryngol Head Neck Dis, 2017
  71. Homeopathic mistletoe adverse reaction mimics nodal involvement in 18F-FDG PET/CT performed for evaluation of response to chemotherapy in lymphoma. Rev Esp Med Nucl Imagen Mol, 2017
  72. Fever Therapy With Intravenously Applied Mistletoe Extracts for Cancer Patients: A Retrospective Study. Integr Cancer Ther, 2017
  73. Breast Cancer Integrative Oncology Care and Its Costs. Integr Cancer Ther, 2017
  74. [Study for the treatment of nonmuscle invasive bladder cancer : A phase III efficacy trial for intravesical instillation of mistletoe extract in superficial bladder cancer (TIM) - AB 40/11 of the AUO]. Urologe A, 2016
  75. Use of complementary and alternative medicine by pediatric oncology patients during palliative care. Support Care Cancer, 2016
  76. Cancer Patients' Experiences of Using Mistletoe (Viscum album): A Qualitative Systematic Review and Synthesis. J Altern Complement Med, 2016
  77. Chemical Pleurodesis Using Mistletoe Extraction (ABNOVAviscum(®) Injection) for Malignant Pleural Effusion. Ann Thorac Cardiovasc Surg, 2016
  78. Editorial. Cell Mol Biol (Noisy-le-grand), 2015
  79. High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer: A Retrospective Case Series. Perm J, 2015
  80. [Secondary prevention in patients with superficial urothelial carcinoma]. Urologe A, 2015
  81. [Study on the treatment of nonmuscle invasive bladder cancer: A phase III efficacy study for intravesical instillation of mistletoe extract in superficial bladder cancer (TIM) AB 40/11 of the AUO]. Urologe A, 2015
  82. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology. Integr Cancer Ther, 2015
  83. Disappearance of an advanced adenomatous colon polyp after intratumoural injection with Viscum album (European mistletoe) extract: a case report. J Gastrointestin Liver Dis, 2014
  84. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Dtsch Arztebl Int, 2014
  85. Tumour response following high-dose intratumoural application of Viscum album on a patient with adenoid cystic carcinoma. BMJ Case Rep, 2014
  86. Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin. Ecancermedicalscience, 2014
  87. Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial. Evid Based Complement Alternat Med, 2014
  88. The case for mistletoe in the treatment of laryngeal cancer. J Laryngol Otol, 2014
  89. Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis. Integr Cancer Ther, 2014
  90. "Mistletoe sign": probably a new dermoscopic descriptor for melanoma in situ and melanocytic junctional nevus in the inflammatory stage. Postepy Dermatol Alergol, 2013
  91. The effect of complementary and alternative medicine on the quality of life of cancer survivors: a systematic review and meta-analyses. Complement Ther Med, 2013
  92. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC Cancer, 2013
  93. Durable response of cutaneous squamous cell carcinoma following high-dose peri-lesional injections of Viscum album extracts--a case report. Phytomedicine, 2013
  94. Anti-cancer, anti-inflammatory and anti-microbial activities of plant extracts used against hematological tumors in traditional medicine of Jordan. J Ethnopharmacol, 2013
  95. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. BMC Complement Altern Med, 2012
  96. Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis. Explore (NY), 2012
  97. Durable Regression of Primary Cutaneous B-Cell Lymphoma Following Fever-inducing Mistletoe Treatment: Two Case Reports. Glob Adv Health Med, 2012
  98. Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Alternat Med, 2012
  99. An exploratory study on the quality of life and individual coping of cancer patients during mistletoe therapy. Integr Cancer Ther, 2012
  100. Oral cancer treatment and immune targets - a role for dendritic cells? J Craniomaxillofac Surg, 2012
  101. Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects. BMC Complement Altern Med, 2011
  102. [Clinical research on anthroposophic medicine:update of a health technology assessment report and status quo]. Forsch Komplementmed, 2011
  103. Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters. BMC Complement Altern Med, 2011
  104. Anthroposophic supportive treatment in children with medulloblastoma receiving first-line therapy. J Pediatr Hematol Oncol, 2011
  105. Herbal therapy use by cancer patients: a literature review on case reports. Eur J Cancer, 2011
  106. Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract. Phytomedicine, 2011
  107. Treatment of clinically diagnosed equine sarcoid with a mistletoe extract (Viscum album austriacus). J Vet Intern Med, 2010
  108. Sustained partial remission of metastatic pancreatic cancer following systemic chemotherapy with gemcitabine and oxaliplatin plus adjunctive treatment with mistletoe extract. Onkologie, 2010
  109. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther, 2010
  110. Pharmacokinetics of natural mistletoe lectins after subcutaneous injection. Eur J Clin Pharmacol, 2010
  111. Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Curr Mol Med, 2010
  112. Complementary and alternative medicine in lung cancer patients: a neglected phenomenon? Front Radiat Ther Oncol, 2010
  113. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forsch Komplementmed, 2009
  114. Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res, 2009
  115. [Favourable course of persisting malignant ascites]. Forsch Komplementmed, 2009
  116. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer (Auckl), 2009
  117. Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series. Phytother Res, 2009
  118. In vitro screening for the tumoricidal properties of international medicinal herbs. Phytother Res, 2009
  119. Complementary and alternative medicine in patients with chronic lymphocytic leukemia. Support Care Cancer, 2009
  120. Mistletoe in conventional oncological practice: exemplary cases. Integr Cancer Ther, 2008
  121. Complementary and alternative treatment methods in children with cancer: A population-based retrospective survey on the prevalence of use in Germany. Eur J Cancer, 2008
  122. Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001). Eur J Cancer, 2008
  123. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Eur J Med Res, 2008
  124. Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. Anticancer Res, 2008
  125. [Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolerability]. Forsch Komplementmed, 2008
  126. Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer, 2008
  127. In vitro response of stimulated B-CLL lymphocytes of patients treated with Viscum album L. extracts. Anticancer Res, 2007
  128. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador. Arzneimittelforschung, 2007
  129. Course of mitogen-stimulated T lymphocytes in cancer patients treated with Viscum album extracts. Anticancer Res, 2007
  130. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). Forsch Komplementmed, 2007
  131. Successful treatment of metastatic malignant melanoma with Viscum album extract (Iscador M). J Altern Complement Med, 2007
  132. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res, 2007
  133. Therapeutic use of mistletoe for CD30+ cutaneous lymphoproliferative disorder/lymphomatoid papulosis. J Eur Acad Dermatol Venereol, 2007
  134. Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. a randomized phase III trial. Forsch Komplementmed, 2007
  135. Subcutaneous inflammation mimicking metastatic malignancy induced by injection of mistletoe extract. BMJ, 2006
  136. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. Eur J Med Res, 2006
  137. Immune modulation using mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung, 2006
  138. In vitro immunoreactivity towards lectin-rich or viscotoxin-rich mistletoe (Viscum album L.) extracts Iscador applied to healthy individuals. Arzneimittelforschung, 2006
  139. [Anthroposophic medicine: health technology assessment report - short version]. Forsch Komplementmed, 2006
  140. [Correlation of NK cell activity against autologous tumour cells and K562 cells with the clinical outcome during therapy with mistletoe extracts]. Forsch Komplementmed, 2006
  141. Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract. Anticancer Res, 2006
  142. Palliative in-patient cancer treatment in an anthroposophic hospital: I. Treatment patterns and compliance with anthroposophic medicine. Forsch Komplementmed, 2006
  143. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res, 2006
  144. Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther, 2006
  145. [Mistletoe (Viscum album) preparations: an optional drug for cancer patients?]. Harefuah, 2006
  146. Mistletoe treatments for minimising side effects of anticancer chemotherapy. GMS Health Technol Assess, 2006
  147. [Influence of ML-1 standardized mistletoe extract on the quality of life in head and neck cancer patients]. HNO, 2006
  148. Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. Anticancer Res, 2005
  149. Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer. Anticancer Res, 2005
  150. Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients. Anticancer Res, 2005
  151. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract. J Urol, 2005
  152. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. Eur J Cancer, 2005
  153. Influence of complementary Viscum album (Iscador) administration on microcirculation and immune system of ear, nose and throat carcinoma patients treated with radiation and chemotherapy. Anticancer Res, 2005
  154. Anaphylaxis to viscotoxins of mistletoe (Viscum album) extracts. Ann Allergy Asthma Immunol, 2005
  155. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol, 2004
  156. Delayed-type hypersensitivity reaction with iscador M given in combination with cytotoxic chemotherapy. J Clin Oncol, 2004
  157. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use". Forsch Komplementarmed Klass Naturheilkd, 2004
  158. Randomized and double-blind studies--demands and reality as demonstrated by two examples of mistletoe research. Forsch Komplementarmed Klass Naturheilkd, 2004
  159. [Problems of randomized studies in complementary medicine demonstrated in a study on mistletoe treatment of patients with breast cancer]. Forsch Komplementarmed Klass Naturheilkd, 2004
  160. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res, 2004
  161. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks. Anticancer Res, 2004
  162. Development and validation of an instrument to measure the effects of a mistletoe preparation on quality of life of cancer patients: the Life Quality Lectin-53 (LQL-53) Questionnaire. Qual Life Res, 2004
  163. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res, 2004
  164. Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study. Anticancer Res, 2003
  165. [Role of immunomodulatory treatment with Iscador QuS and Intron A of women with CIN1 with concurrent HPV infection]. Ginekol Pol, 2003
  166. [Retrospective study of malignant melanoma patients treated with mistletoe extracts]. Forsch Komplementarmed Klass Naturheilkd, 2003
  167. Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res, 2003
  168. Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: a placebo-controlled evaluation in healthy subjects. J Altern Complement Med, 2002
  169. [Blood and tissue eosinophilia, mistletoe lectin antibodies and quality of life in a breast cancer patient undergoing intratumoral and subcutaneous mistletoe therapy]. Forsch Komplementarmed Klass Naturheilkd, 2002
  170. Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does viscum album treatment affect these parameters? Biomed Pharmacother, 2002
  171. Activation of dendritic cells by an aqueous mistletoe extract and mistletoe lectin-3 in vitro. Anticancer Res, 2002
  172. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals. Eur J Med Res, 2002
  173. Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.). Allergol Immunopathol (Madr), 2001
  174. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study. Eur J Med Res, 2001
  175. [Effects of an adjuvant mistletoe therapy in patients with surgically treated head and neck neoplasms: a randomized clinical trial]. Strahlenther Onkol, 2001
  176. [Metaphorical aspects of mistletoe therapy in patients' experiences--a qualitative study]. Forsch Komplementarmed Klass Naturheilkd, 2001
  177. Expression of interleukin-4 in apoptotic cells: stimulation of the type-2 cytokine by different toxins in human peripheral blood mononuclear and tumor cells. Cytometry, 2000
  178. [Oncologic mistletoe therapy: physicians' use and estimation of efficiency]. Dtsch Med Wochenschr, 2000
  179. Hypereosinophilia induced by high-dose intratumoral and peritumoral mistletoe application to a patient with pancreatic carcinoma. J Altern Complement Med, 2000
  180. [Mistletoe extracts in the therapy of malignant, hematological and lymphatic diseases--a monocentric, retrospective analysis over 16 years]. Forsch Komplementarmed Klass Naturheilkd, 2000
  181. [Favorable long-term outcome with mistletoe therapy in a patient with centroblastic-centrocytic non-Hodgkin lymphoma]. Dtsch Med Wochenschr, 1999
  182. [Iscador QuS and human recombinant interferon alpha (Intron A) in cervical intraepithelial neoplasia (CIN)]. Przegl Lek, 1999
  183. Decrease of activated lymphocytes four and nine hours after a subcutaneous injection of a Viscum album L. extract in healthy volunteers. Nat Immun, 1998
  184. Subcutaneous infiltrates induced by injection of mistletoe extracts (Iscador). Am J Ther, 1998
  185. Detection of inflammation- and neoplasia-associated alterations in human large intestine using plant/invertebrate lectins, galectin-1 and neoglycoproteins. Acta Anat (Basel), 1998
  186. Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy. Eur J Med Res, 1998
  187. Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res, 1998
  188. [Use of alternative medicine among Norwegian hospitalized cancer patients]. Tidsskr Nor Laegeforen, 1997
  189. Clinical relevance of immunoactive mistletoe lectin-I. Anticancer Drugs, 1997
  190. Stimulation of antitumour immunity by intrapleural instillation of a Viscum album L. extract. Anticancer Drugs, 1997
  191. Site of mistletoe injection observed on In-111 OncoScint imaging. Clin Nucl Med, 1997
  192. Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res, 1996
  193. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res, 1996
  194. The use of non-proven therapy among patients treated in Norwegian oncological departments. A cross-sectional national multicentre study. Eur J Cancer, 1995
  195. [Immunoactive effects of various mistletoe lectin-1 dosages in mammary carcinoma patients]. Arzneimittelforschung, 1995
  196. Mistletoe treatment for cancer review of controlled trials in humans. Phytomedicine, 1994
  197. Is the binding of mistletoe lectins I and III a useful prognostic indicator in colorectal carcinoma? Eur J Surg Oncol, 1994
  198. [Unconventional therapeutic methods in superficial bladder cancer]. Urologe A, 1994
  199. Phenotype-associated lectin-binding profiles of normal and transformed blood cells: a comparative analysis of mannose- and galactose-binding lectins from plants and human serum/placenta. Eur J Cell Biol, 1994
  200. Enhancement of MHC-unrestricted cytotoxic activity of human CD56+ CD3- natural killer (NK) cells and CD3+ T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets. J Cancer Res Clin Oncol, 1994
  201. Improvement of DNA repair in lymphocytes of breast cancer patients treated with Viscum album extract (Iscador). Eur J Cancer, 1991
  202. [Vysorel/Isorel--cancer drug from Viscum album. Documentation No.20]. Schweiz Rundsch Med Prax, 1990
  203. [Helixor--mistletoe preparation for cancer therapy. Documentation No. 19]. Schweiz Rundsch Med Prax, 1990
  204. A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol Immunother, 1990
  205. Apparent response of small cell lung cancer to an extract of mistletoe and homoeopathic treatment. Thorax, 1989
  206. Influence of carbohydrates on the cytotoxicity of an aqueous mistletoe drug and of purified mistletoe lectins tested on human T-leukemia cells. Arzneimittelforschung, 1989
  207. [Iscador--mistletoe extract for cancer treatment. Documentation No. 10]. Schweiz Rundsch Med Prax, 1988
  208. [What prospects of success does Iscador therapy offer in advanced ovarian cancer?]. Onkologie, 1979
  209. [Prevention of recurrence of bronchial carcinomas after surgery by means of the mistletoe extract Iscador. Results of a clinical study from 1969-1971]. Onkologie, 1978
  210. [Topical treatment of malignant pleural effusions with iscador, a mistletoe preparation (author's transl)]. Prax Klin Pneumol, 1978
  211. [The local treatment of malignant pleural exudations with Iscador (a drug obtained from Misteltoe). Preliminary report (author's transl)]. Osterr Z Onkol, 1977
  212. [After care of irradiated genital carcinoma using the Viscum album preparation Iscador for the prevention of recurrences]. Med Klin, 1967

Other conditions Mistletoe extract has been studied for

Checked against PubMed on 2026-10-28. Everything we know about Mistletoe extract